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CHAPTER 1 INTRODUCTION
1.1 Antimicrobial resistance
Microorganisms not only have a much longer history than human beings, they exist in
greater quantities as well. Life on earth has a history of 3.7 billion years, 3 billion years of
which microorganisms have been the single dominant form.1-2 They are found from the
highest mountains to the deepest trenches; their biochemical reactions shaped the
biosphere that we now live in today.3-4 If we were to summarize the earth’s history into one
calendar year with the earth born on Jan 1st, the first two months would be barren, but from
sometime in March, tiny microbes would start swimming in the warm coastal waters and
around thermal vents. From March to October, two thirds of a year, microbes were the only
life form; humans arrived on the last hour of the last day (Dec 31st) and have existed for no
more than 30 minutes. The sheer quantity of microbes is almost beyond imagination. If we
gather all the microbes on earth, not only would they outnumber all the humans, trees, pets,
birds – all the visible world combined, they would outweigh them as well!5 As a late comer
who falls short in number, it is no wonder that humans have developed mechanisms to
coexist with microbes.
Microbes do not just live with us, they also live on us. The exact number of microbes
living on each person is still under debate. The most well-known ratio is 1:10,6-7 with
microbes outnumbering human cells. A closer look suggests this famous ratio is perhaps
only a back-of-the-envelope calculation8 with a more accurate estimate being that each
human contains about 30 trillion human cells and 39 trillion microbial cells8 – nearly a tie.
By any standard however, we are walking ecosystems and “we contain multitudes” as the
science journalist Ed Yong puts it.9 We live in harmony with most of these microbes; some
are even beneficial, they help us digest food, build immune systems, and may even
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contribute to our mental health.10-11 Occasionally however, some microbe-human
relationships go rogue, with devastating consequences.
Before 1940, infections were a leading cause of death.12 The standard treatment for
tuberculosis used to be fresh air; any chance of infection, even a paper cut could be fatal.
The advent of antibiotics, considered by many to be one of the greatest achievements in
modern medicine, has greatly reduced the mortality of bacterial infections in the United
States and around the globe.13-14 Antibiotics, together with vaccination, sanitation and better
hygiene practices to control infectious diseases15 contribute to an increase in successful
child birth, a sharp drop in infant and child mortality16 and doubling of the average lifespan.17
Unfortunately, resistance has accompanied antibiotics from nearly the first day of their
use18-19 and the influences of resistance have grown constantly over time.20-21
Contrary to popular belief, resistance is not a new phenomenon. The first reports of a
pathogen developing resistance to penicillin appeared in 1944,22-24 a mere year after the
drug began to be mass produced in 1943. Even Alexander Fleming, the discoverer of
penicillin, warned of the development of resistance in his 1945 Nobel Prize acceptance
speech.25 He described a hypothetical scenario where Patient X, who:
buys some penicillin and gives himself, not enough to kill the streptococci but enough
to educate them to resist penicillin. He then infects his wife. Mrs. X gets pneumonia and
is treated with penicillin. As the streptococci are now resistant to penicillin the treatment
fails. Mrs. X dies.
Indeed, resistance has been found for every antibiotic ever discovered.26-27
The origin of antibiotic resistance can be dated long before antibiotics being used by
humans28-30 as studies have shown that antibiotic biosynthetic pathways and antibiotic
resistant mechanisms began to co-evolve at least 30,000 years ago.31-32 Consistent with
this notion is the finding that antibiotic resistance occurs in microbes isolated from extreme
natural habitats including the deep ocean33 and deep terrestrial subsurface34, places
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presumably that have little human influence.35-36 These reports suggest the unpleasant
conclusion that resistance cannot be eradicated and thus humans must continue to develop
new agents to treat otherwise intractable bacterial infections.37-40
Historically, resistance was not a big concern because new antibiotics kept being
launched into the market. From the discovery of the antimicrobial effects of sulfonamides in
1932 by the German bacteriologist and pathologist Gerhard Domagk, penicillin and
streptomycin were discovered in 1943, tetracycline in 1945, cephalosporin in 1948,
erythromycin in 1949, and vancomycin in the 1950s. New classes of antibiotics were
constantly emerging, not to mention upgrades of existing ones were also occurring.
Since the end of the so-called “golden era” of antibacterial drug discovery in the 1970s,
however, only two new classes of antibiotics have been launched to the market, linezolid4142

and daptomycin.43-45 Not unexpectedly, resistance to both have been detected46-51.

Unfortunately, the rate of antibacterial discovery has slowed dramatically, and many big
pharmaceutical companies have stopped developing new antibiotics.52-54 Based on a review
article published in 2016,55 there are only 40 products in the antibiotic pipeline, compared
to more than 120 compounds for treatment of non-small cell lung cancer and melanoma
alone, for example.
Antimicrobial resistance has enormous health and economic implications. It is estimated
that antimicrobial resistance is directly responsible for 23,000 deaths annually in the United
States56 and more than 25,000 in the European Union.57-58 A conservative estimate of the
economic cost of bacterial resistance in the United States is $20 billion in healthcare costs
and $35 billion in societal costs annually.59 Moreover, since antibiotics are often used as
prophylaxis, resistance has the potential to lead us back to a pre-antibiotic world.60-61 For
example, surgeries would become more dangerous. Economists have used hip
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replacements as an example and estimated that the infectious rate would rise from 0.5-2%
currently (with antibiotics) to 40-50% without effective antibiotics and 30% of patients would
die.62 The most authoratative prediction of the impact of antimicrobial resistance was
published in the Review on Antimicrobial Resistance by a team lead by the world-renowned
macroeconomist Lord Jim O’Neill,63 former chairman of Goldman Sachs Asset Management,
and former British government minister. He estimated that by 2050, based on the current
rate of resistance and if no interventions take place, deaths from antimicrobial resistance
could skyrocket to 10 million each year and cost $100 trillion globally. No other diseases
except pandemic influenza can make such a claim. In fact, if the current trend is not altered,
antimicrobial resistance could become the world’s single greatest killer, surpassing heart
disease or cancer.64
In 2013, the Centers for Disease Control and Prevention (CDC) published a list of 18
drug-resistance threats to the United States.65 The list was further grouped into three
different urgent categories: urgent, serious and concerning threats (Table 1). Three bacteria
were

listed

in

the

urgent

threat

category:

C.

difficile,

carbapenem-resistant

Enterobacteriaceae and N. gonorrhoeae.65 The first two usually affect patients in medical
facilities and/or those being treated with other antibiotics; however N. gonorrhoeae is a
sexually transmitted disease that can infect healthy people.66-67 In early 2018, a man in the
United Kingdom was diagnosed with a strain of N. gonorrhoeae that is resistant to all
existing classes of antibiotics, perhaps the first occurrence of such an infection.68 The
sexual transmission of these strains means that antibiotic resistance could spread much
more rapidly. Twelve additional bacterial strains were grouped in the serious threat
catogory.65 Among them are notorious bacteria such as multidrug-resistant Pseudomonas
aeruginosa, methicillin-resistant S. aureus (MRSA), and drug-resistant M. tuberculosis. A
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fungal infection, fluconazole-resistant Candida, was also included in the list. Candida is
ranked 4th in a list of the most common hospital-acquired bloodstream infections,69 and it is
estimated to cause more than 400,000 cases annually, mostly in developed countries.70
Vancomycin-resistant S. aureus (VRSA) was in the concerning threat group.65
Table 1. Drug-resistant threat to the United States.
Threat level

Microbes

Urgent

C. difficile
Carbapenem-resistant Enterobacteriaceae
Drug-resistant N. gonorrhoeae

Serious

Multidrug-resistant Acinetobacter
Drug-resistant Campylobacter
Fluconazole-resistant Candida
Extended specturm β-lactamase producing Enterobacteriaceae (ESBLs)
Vancomycin-resistant Enterococcus (VRE)
Multidrug-resistant Pseudomonas aeruginosa
Drug-resistant non-typhoidal Salmonella
Drug-resistant Salmonella Typhi
Drug-resistant Shigella
Methicillin-resistant Staphylococcus aureus (MRSA)
Drug-resistant Streptococcus pneumoniae
Drug-resistant tuberculosis

Concerning

Vancomycin-resistant Staphylococcus aureus (VRSA)
Erythromycin-resistant Group A Streptococcus
Clidamycin-resistant Group B Streptococcus
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Clearly, the threat of infections from resistant micobes is real. There is an urgent and
growing need for new antibiotics, particularly ones with novel mechanisms of action. One
potential target for new therapeutics lies in the de novo purine biosynthetic pathway.
1.2 Purine nucleotide biosynthesis
Nucleotides play a variety of essential roles in cellular function. Most notably, they are
the building blocks of DNA and RNA and act as carriers of chemical energy (ATP and to
some extent GTP). Nucleotides are also components of cofactors such as NAD, FAD and
coenzyme A and they can act as chemical messengers, such as cAMP and cGMP.71 The
concentration of nucleotides in cells varies by its function and tissue type. The concentration
of ATP concentration is quite high, while the cellular pools of other nucleotides are usually
limited to less than that needed to synthesize 1% of the genome.71 Therefore, cells must
constantly make nucleotides during rapid proliferation, suggesting that relevant biosynthetic
enzymes may be logical targets against rapid dividing cells in diseases such as cancer and
infections.72 Inhibitors against nucleotides biosynthesis, such as fluorouracil, methotrexate
and mercaptopurine are valid and important chemotherapeutic and anti-viral agents.
1.2.1 Salvage pathway71
Given the critical nature of purine nucleotides to life, it is not surprising that there are
two pathways for their synthesis: the de novo and the salvage pathways. De novo synthesis
assembles nucleotides from basic metabolic precursors, including amino acids, ribose 5phosphate, CO2, and NH3 (Figure 1). The salvage pathways recycles free bases released
from

nucleic

acid

breakdown.

Free

adenine

is

salvaged

by

adenosine

phosphoribosyltransferase which catalyzes the reaction of adenine with phosphoribosyl
pyrophosphate (PRPP) to yield adenosine nucleotide. Free guanine and hypoxanthine are
recycled in the same way by hypoxanthine-guanine phosphoribosyltransferase. These
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salvage

pathways

play

an

important

role

in

recycling

nucleotides

from

the

environment/tissue, and are usually considered necessary for maintaining cellular functions,
while the de novo pathway is required for cell division.

Figure 1. Precursors of inosine monophosphate used in de novo purine biosynthesis. PR
is ribose phosphate.
1.2.2 De novo pathway
In mammalian cells, the de novo synthesis of purines (Figure 2) starts from PRPP and
takes 10 steps, while consuming 4 molecules of ATP. Microbes undergo a similar process
except one additional energy-consuming step is necessary.73-75 Thus, in microbes, 11 steps
are needed along with 5 molecules of ATP. The detailed pathway of purine biosynthesis
was worked out primarily by John Buchanan and G. Robert Greenberg in the 1950s from
isotopic tracing experiments.71 Atoms from basic precursors are connected to ribose
phosphate creating the purine ring in a step-wise manner.
In the first committed step, N-9 is connected to the sugar. An amino group, donated by
glutamine, is attached to the C-1 position of PRPP yielding 5-phosphoribosylamine (PRA),
a short-lived intermediate with a half-life of only 38 seconds at pH 7.5.76 In the second step,
C-4, C-5 and N-7 are added onto the amino group of PRA from glycine, resulting in
glycinamide ribonucleotide (GAR). ATP is used in this step to activate the glycine carbonyl
group for condensation with the amine. Formylation of the amino group of GAR occurs in
the third step to give N10-formyl glycinamide ribonucleotide (FGAR); this reaction adds C-8.
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The fourth step converts the amide from the second reaction into an imine and adds N-3 by
the addition of ammonia (from glutamine), while also consuming a molecule of ATP. The
fifth step a is dehydration and ring closure reaction, yielding the five-membered ring,
aminoimidazole ribonucleotide (AIR). This step requires ATP to activate the formyl group.
At this point, the five-membered ring and three atoms of the six-membered ring (N-3, C-4,
and C-5; C-4 and C-5 are shared between the two rings) are in place, requiring the addition
of another two carbons and one nitrogen atom. C-6 is added in the sixth step, which
represents a major difference between mammalian and microbial de novo purine
synthesis.73-75 In mammals, carbon dioxide is added directly to the C-5 of AIR to generate
carboxyaminoimidazole ribonucleotide (CAIR). In microbes, bicarbonate and ATP are used
to add CO2 to the exocyclic amine of AIR (N-3) to generate N5-carboxyaminoimidazole
ribonucleotide (N5-CAIR). Rearrangement of the CO2 group from N-3 to C-5 later generates
CAIR. A detailed description of this clade-specific divergence is provided in the following
section. The seventh and eighth steps add the last nitrogen (N-1) to the skeleton via an
energy-consuming amide bond forming reaction between C-6 and aspartate amino group
followed by the elimination of fumarate to give aminoimidazole-4-carboxamide
ribonucleotide (AICAR). The final carbon, C-2, is contributed by N10-formyltetrahydrofolate.
The last step is a second ring closure event, yielding the purine nucleus inosine
monophosphate (IMP). IMP is then converted to GMP and AMP by subsequent enzymes.
For clearness and simplicity, enzymes involved in de novo synthesis are not described
in the text above. Abbreviations of the enzyme names are used in Figure 2 and throughout
the following text. Full names of the enzymes are listed in Table 3.
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Figure 2. De novo purine biosynthetic pathway.
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Table 2. List of abbreviations of intermediates in de novo purine biosynthetic pathway.
Abbreviations

Full names

PRPP

5-Phosphoribosylpyrophosphate

PRA

5-Phospho-D-ribosylamine

GAR

Glycinamide ribonucleotide

FGAR

N-Formylglycinamide ribonucleotide

FGAM

N-Formylglycinamidine ribonucleotide

AIR

Aminoimidazole ribonucleotide

N5-CAIR

N5-Carboxyaminoimidazole ribonucleotide

CAIR

Carboxyaminoimidazole ribonucleotide

SAICAR

Succino 5-aminoimidazole-4-carboxamide ribonucleotide

AICAR

Aminoimidazole-4-carboxamide ribonucleotide

FAICAR

5-Formamido-4-imidazolecarboxamide ribonucleotide

IMP

Inosine monophosphate
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Table 3. List of abbreviations of enzymes in de novo purine biosynthetic pathway.
Gene name

Enzyme Abbreviations

Enzyme Full names

purF

PurF

Aminophosphoribosyltransferase

purD

PurD

GAR synthetase

purN

PurN

GAR transformylase

purT

PurT

FGAR synthetase

purL

PurL

FGAR synthetase

purM

PurM

AIR synthetase

purE (Class II)

PurE Class II

AIR carboxylase

purK

PurK

N5-CAIR synthetase

purE (Class I)

PurE Class I

N5-CAIR mutase

purC

PurC

SAICAR synthetase

purB

PurB

SAICAR lyase

purH

PurH

AICAR transformylase

purP

PurP

AICAR synthetase

purJ

PurJ

IMP cyclohydrolase

purO

PurO

IMP cyclohydrolase

1.3 Divergences in the de novo pathway
Several differences exist between prokaryotes and eukaryotes in the enzymes
catalyzing the de novo pathway. These represent potential novel antimicrobial targets and
are outlined and discussed in detail here.
PurF: PurF catalyzes the first step in de novo purine synthesis, which is the conversion
from PRPP to PRA. Structurally, two types of PurF have been found. The first is found in
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higher vertebrates, plants, cyanobacteria, and Gram-positive bacteria, while the second is
from yeast and Gram-negative bacteria.77-80 The main difference is that the first type
contains a structural Fe4S4 cluster81 and a cleavable N-terminal propeptide, while the
second does not. PurFs from B. subtilis82-83 and E. coli84-85 have been studied extensively.
The two enzymes share 40% sequence identity and are structurally homologous.
PurD: Only one known enzyme PurD catalyzes the second step, from PRA to GAR. In
E. coli, it is a single enzyme, in higher organisms, however, PurD is fused with PurM and
PurN forming a trifunctional enzyme.
PurN/PurT: Two different enzymes catalyze the third, formylation step. PurN is found in
most organisms and formylates the amino group using N10-formyltetrahydrofolate. In higher
organisms, PurN is the C-terminal domain of the trifunctional enzyme PurD-PurM-PurN.
Researchers have investigated human PurN as an anticancer target.86-92 E. coli can use an
alternative enzyme PurT to catalyze this transition, and some archeabacteria have been
found to rely solely on PurT. PurT is an ATP-grasp enzyme93-94 and catalyzes the ATPassisted ligation directly using formate as the carbon source.95-96 Being a redundant
metabolic enzyme, PurT is generally not considered a therapeutic target. A recent study
from Denmark however demonstrated that single-gene deletion of either purT or purN
resulted in attenuation in Salmonella enterica serovar Typhimurium.97 This result suggests
a revisit of the redundancy relationship of PurT and PurN is merited.
PurL: Two different types of PurL have been found, termed large and small based on
their respective sizes. Large PurL is found in eukaryotes and Gram-negative bacteria, while
small PurL is found in Gram-positive bacteria and archaea.72, 98-99 Large PurL has three
domains: the glutaminase, the FGAM synthetase, and the N-terminal domains. The
glutaminase domain produces ammonia, which is then channeled to the FGAM synthetase
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domain.100 The N-terminal domain helps to form the ammonia channel that links the other
two catalytic domains.98 Small PurL only contains the FGAM synthetase domain and
requires assistance from PurQ and PurS to complete its function.98, 101 PurQ is homologous
to the glutaminase domain in large PurL,102 while PurS is similar to the N-terminal domain.103
Recently, researchers have reconstructed the PurLSQ complex from B. subtilis and small
molecules such as MgADP and glutamine have proved necessary for complex formation.99
PurK, class I and II PurE (Figure 3): The largest divergence in the de novo purine
synthesis pathway lies in the steps used to convert AIR to CAIR. Mammalian cells and
microbes utilize different enzymes and different intermediates to complete this process.7375, 104

In vertebrates, it is a one-step conversion;74 however, two individual steps are needed

in bacteria,73, 75, 104 yeast, and fungi.105 In human cells, AIR is carboxylated by class II PurE
to CAIR directly utilizing CO2 as the carbon source.74, 105-107 No energy is needed in this
transition. Mechanistically, direct carboxylation without co-factors such as biotin is unusual,
and this step has attracted investigation from many researchers.108 In bacteria, yeast, and
fungi, this conversion is broken down into two sequential steps. AIR is first converted by
PurK to N5-CAIR using HCO3- as the one carbon source and consuming one molecule of
ATP.75, 104 N5-CAIR then undergoes direct CO2 transfer from N5 to C4 to generate CAIR.109110

This second reaction is catalyzed by class I PurE. One type of bacteria however, the

spirochete dental pathogen Treponema denticola, was found to contain a class II PurE with
no PurK, and this is the first and only example of a prokaryotic class II PurE.111
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Figure 3. Divergence between microbial and human de novo purine pathway. PR is ribose
phosphate.
Class I and II PurEs both form octamers in the native state,106,

110, 112-113

and their

structures can be largely superimposed. They also share considerable sequence
similarities. It is intriguing how these two almost identical enzymes catalyze distinct
reactions. In human cells, class II PurE is fused with PurC to form a bifunctional enzyme.110
A third type of PurE is found in archaea. Some methanobacteria have a purE-purE’ gene
that encodes a 37 kDa polypeptide,114 twice the length of both Class I and II PurE. The Cterminus half of the polypeptide can be aligned with its N-terminus half with 36% identity.
Only the N-terminal half contains the universally conserved active site residues that exist in
both class I and class II PurE, and its sequence can be characterized as a class I PurE by
class-specific residues.115 Although sequence alignment suggests methanogens contain a
class I PurE, the whole protein encoded by the M. thermoautotrophicum purE-purE’ gene
has been purified and characterized to be a pure class II PurE utilizing AIR and CO 2 as
substrates without ATP.116 Complementary assays have been conducted on the M. smithii
whole purE-purE’ gene and several truncated versions. Only the complete sequence can
complement both PurK and PurE deficient E. coli strains; deletions of peptides of the length
of 9 kDa, 25 kDa, 28 kDa and 30 kDa from the C-terminus, or even 7 amino acids at the
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beginning of the C-terminus half abolished its ability to complement either PurK or PurE
deficient strains.117-118 The methanogen PurE-PurE’ is the only identified PurE which may
have an N-terminal PurE fused with other proteins. In other fused PurE system, such as the
human bi-functional PurCE,74, 106 yeast bi-functional PurKE,105 the PurEs are all at the Cterminus. No PurK homolog has been found in these organisms.
In contrast with the three different types of PurEs, PurK is found only in microbes and
does not have any human homologs. It is a separate enzyme in bacteria but fused with
class I PurE as a bifunctional enzyme in fungi.105 PurK is a member of the ATP-grasp
enzyme superfamily119-120 and it forms a dimer in its native state.121
PurH, PurJ/PurP,PurO: Archaea use different enzymes in the last two steps compared
to bacteria and eukaryotes. PurH and PurJ are found in bacteria and eukarya,122 while PurP
and PurO occur in archaea.123 PurH catalyzes formylation of AICAR in a manner similar to
PurN, using N10-formyltetrahydrofolate as a cofactor.124 In contrast, PurP is like PurT,
catalyzing an ATP-assisted ligation of AICAR with formate.123 PurHJ is a bi-functional
enzyme122, 125 and has been explored as an anticancer target.126-127
1.4 Target verification of PurK
Since the differences in the step from AIR to CAIR is divided strictly from mammalian
cells to microbes, it is logical to explore PurK and microbial class I PurE as potential
antimicrobial targets. There have been published studies on the development of inhibitors
of both PurE128-129 and PurK.130 The development of PurE inhibitors is challenging because
Class I and Class II PurEs are evolutionarily related. They each form an octamer in the
native state, and their structures can be largely superimposed. They also share
considerable sequence similarities complicating the discovery of class-specific inhibitors.
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Indeed, the only known selective inhibitor of PurE shows selectivity for Class I over Class II
PurE.108, 129
PurK, on the other hand, does not have any human homologs. Therefore, it is more
likely that selective antimicrobial agents targeting PurK could be identified. Genetic studies
on PurK support the role of the enzyme in microbial growth and disease progression. In the
1950s, Bacon described the loss of virulence of Bacterium typhosum mutants with purine
synthesis deficiencies in a murine intraperitoneal infection model.131-133 Studies with
different microorganisms, such as S. aureus,134 Bacillus anthracis,135 Candida albicans,136
and Cryptococcus neoformans137 both in vivo and in vitro have given similar results. These
results have also shown that the salvage pathway alone is not sufficient to produce enough
purines for growth, validating the de novo purine pathway as an antimicrobial target. Taken
together, both biochemical and genetical evidence support that PurK is an attractive
antimicrobial target.
1.5 Previous attempts at PurK inhibitor development
Despite intensive biochemical and structural investigations of PurK, no one has
developed selective inhibitors of this enzyme. To fill in this gap, our lab previously conducted
a high-throughput screening study.130 Using a UV-based discontinuous assay measuring
the free phosphate concentration in the system, we screened a 48,000 drug-like
commercially available library. The screen identified 14 hits; however, additional studies
revealed that none of these agents actually bound to PurK. Instead, 12 out of 14 agents
covalently reacted with AIR.138 One compound was riboflavin, a vitamin, and several
analogs of the last agent failed to give improved activity against the enzyme. Thus, a new
approach towards identifying inhibitors against PurK was needed. This previous work forms
the basis for this thesis.

17

1.6 ATP-grasp Family
1.6.1 General introduction
One approach towards finding inhibitors is to examine inhibitors of biochemically related
enzymes. PurK belongs to the ATP-grasp enzyme superfamily.112, 121, 139-141 The ATP-grasp
enzymes catalyze the ligation between an amino group and an activated carboxylate.119-120
Activation requires one molecule of ATP to generate a proposed acylphosphate
intermediate,142-143 though this intermediate has not been captured by crystallization.
Enzymes within this family share a large degree of structural similarity among their ATPbinding domains. In fact, the name of this group, ATP-grasp, is derived from the unique
binding orientation of ATP in its ATP-binding site.
Structurally, the ATP-grasp family is characterized by a three-domain architecture with
A, B and C domains93 (Figure 4). The A and C domains form a central cleft where substrates
reside.94, 144 The B domain holds ATP and is flexible upon nucleotide binding.123, 145 The
polyphosphate group of the ATP is firmly bound to a conserved P-loop in the B domain and
interacts with one to three Mg2+ ions.94 The high degree of topological similarity of the ATPbinding domain is the signature of the ATP-grasp enzymes.

Figure 4. General representation of the ATP-grasp enzymes based on the 3-D structure of
the A. clavatus PurK enzyme (PDB ID: 3K5I).
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Mechanistically, the ATP-grasp enzymes catalyze their reactions in a two-step
fashion.146-148 First, the carboxylate is activated by ATP to generate an acylphosphate
intermediate. Second, nucleophilic attack on the activated carbonyl group by the amino
group occurs, eliminating free phosphate and resulting in the final ligation amide product.
About 20 enzymes have been found to belong to this family. Four enzymes in the de
novo purine biosynthetic pathway, PurD, PurT, PurK and PurP belong to this group,
implying evolutionary significance.149 Other ATP-grasp enzymes play important roles in
various critical metabolic pathways, such as fatty acid synthesis, gluconeogenesis and cell
metabolism.119 Another member of this superfamily is biotin carboxylase (BC). BC catalyzes
the first committed step in fatty acid synthesis, which is the ATP-dependent carboxylation
of biotin using HCO3- as the one carbon source.150 Mechanistically, the first half reactions of
BC and PurK are identical, namely the activation of bicarbonate by ATP to generate the
putative common intermediate, carboxyphosphate151-152 (Figure 5a). The second reaction is
the carboxylation of the substrate to generate the desired product and phosphate. Structural
comparisons of both enzymes indicate that the ATP-grasp domains of PurK139-140, 153 and
BC148, 154 can be largely superimposed (Figure 5b). Root mean square deviation (RMSD) in
the aligned ATP-grasp regions is 1.609 Å, and the distances between the 6-NH2 and 2’-OH
of the two aligned ADPs are 1.1 Å and 1.5 Å, respectively.
a. Reaction
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b. Structure

ADP

Figure 5. Similarities between PurK and BC. a. Reaction similarity. b. Crystal structural
superimposition of PurK (pdb: 3K5I, green) and BC (pdb: 2J9G, cyan) with ADP in the
binding sites of both enzymes.
1.6.2 ATP-site inhibitors of ATP-grasp family
It has been estimated that about 9-10% of all enzymes bind ATP, and cells contain ATP
in the millimolar range.155 It is no doubt challenging to develop selective inhibitors against a
particular ATP-binding enzyme while also being able to compete against the high cellular
concentration of ATP. However, kinase and phosphatase inhibitors are mainstream drugs
for important diseases and demonstrate that these challenges can be overcome.156-158 In
contrast, relatively few studies on inhibitors of ATP-grasp enzymes have been reported.
However, one critical study came from Pfizer’s work on BC.159-160
In a phenotypic HTS campaign,160 researchers from Pfizer focused on finding
compounds that inhibited bacteria growth using a library of protein kinase inhibitors. A group
of pyridopyrimidine compounds were found to possess potent antibacterial activity. The
mechanism of action of these compounds was via inhibition of fatty acid synthesis
specifically by targeting the ATP-grasp domain of BC. Investigations of additional analogs
revealed a pyridopyrimidine (compound 1 Figure 6) with a Kd of 0.8 nM against purified E.
coli BC with an IC50 of less than 5 nM in in vitro activity testing. X-ray crystallography studies
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confirmed that these pyridopyrimidines bound to the ATP-site of the ATP-grasp domain of
BC. Researchers also confirmed the selectivity of these agents against other ATP-utilizing
enzymes, demonstrating that the ATP-grasp domain was divergent enough for selective
targeting over protein kinases. Encouraged by these results, follow-up studies159 were
carried out using virtual and fragment-based methods, and additional ATP-site inhibitors
with diverse scaffolds (Figure 6. The rest than compound 1) were identified. These
pioneering proof-of-concept studies demonstrated that bacterial ATP-grasp enzymes could
be selectively targeted over other ATP-utilizing enzymes and that these agents could be
promising antimicrobial compounds. Inspired by the encouraging BC inhibitors published
by Pfizer, a group of researchers from Slovenia and the UK tested the pyridopyrimidines
against D-ala-D-ala ligase and demonstrated moderate inhibition activity.161

Figure 6. ATP-binding site inhibitors of BC developed by Pfizer.
At approximately the same time, a similar study from Schering-Plough was
independently reported.162-164 Using an affinity-based assay coupled with mass
spectroscopy, researchers identified a group of benzimidazole (Figure 7) compounds with
low micromolar affinity against BC. Rapid hit-to-lead research resulted in the best
compound possessing an IC50 of 20 nM with confirmed antibacterial activity. The authors
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demonstrated that these compounds inhibit fatty acid synthesis but spare DNA, RNA, and
protein synthesis. They also validated the target by using an E. coli strain sensitized to BC
inhibitors by overexpression of apo-BCCP. These independent reports of distinct chemical
classes of BC inhibitors demonstrate that the selective targeting of the ATP-grasp domain
can be done and that these agents have the potential to be antimicrobial agents.

Figure 7. ATP-binding site inhibitors of BC developed by Schering-Plough.
Inspired by the reported high potency of ATP-site inhibitors of BC and the similarity
between PurK and BC, we decided to test BC inhibitors to see if they provide a starting
point to further develop selective PurK inhibitors. The results outlined below indicate that
these agents can indeed be inhibitors of PurK, although with modest affinity when compared
to BC. Our results have also provided information on the binding of these agents to PurK.
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CHAPTER 2 RESULTS AND DISCUSSIONS
2.1 Preliminary testing of potent BC inhibitors against PurK
2.1.1 Synthesis
Three potent BC inhibitors (1, 2, and 3 in Figure 6) were selected to test as potential
inhibitors of PurK. These compounds were selected because they are the most potent BC
inhibitors in the Pfizer study and are either synthetically accessible (1 and 2) or
commercially available (3). A fourth compound 4, 6-methylpyrido[2,3-d]pyrimidine-2,4diamine, was selected because it is commercially available and structurally similar to
compound 3 and 1. To reduce the influences of the side chains only keeping the core
scaffold, we deleted the dibromo substituents on the 6-pheny ring of compound 1. The
dibromo compound was later tested as a derivative in section 2.3.2 as compound 11.
Compounds and their numbers used in this preliminary test are listed in Figure 8.

Figure 8. Compounds tested in the preliminary study.
Compound 1 and 2 were made following literature methods159-161 from commercially
available starting materials (Schemes 1 and 2). The approach outlines in scheme 1 gave
the desired heterocyclic pyridopyrimidine starting from the pyrimidine ring. The pyrimidine
was made by a ring formation reaction using commercially available starting materials
guanidine nitrate and (ethoxymethylene)malononitrile. The nitrile group of 1a was readily
reduced to aldehyde (1b) by Raney nickel in formic acid. The final pyrido[2,3-d]pyrimidine
scaffold was prepared through a condensation reaction with benzyl nitrile. The approach
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described in scheme 2 gave the second scaffold to be tested, methyloxazole carboxamide.
This compound was made from the commercially available ethyl 2-methyloxazole-4carboxylate. Base hydrolysis revealed the carboxylic acid group, which was subsequently
activated with HBTU and condensed with dibenzylamine to give the desired amide 2.

Scheme 1. Synthesis of pyrido[2,3-d]pyrimidines. Reagents and conditions: (a) NaH, EtOH,
-5 ºC to r.t., 18 h, 83%; (b) Ra-Ni, 98-100% HCOOH, reflux, 18 h, 89%; (c) NaH,
EtO(CH2)2OH, reflux, 4 h, 84%.

Scheme 2. Synthesis of methyloxazole-carboxamide. Reagents and conditions: (a) 2 M
NaOH, 60 ºC, 45 min, 82%; (b) HBTU, NMM, DMF, r.t., 18 h, 20%.
2.1.2 BC inhibitor pyrido[2,3-d]pyrimidine weakly inhibited PurKAsp
We collected three potent BC inhibitors, 1, 2, 3, and another structurally related
compound 4 and tested them against PurK from E. coli and A. clavatus (Table 4). Residual
activities (RA%) were collected at a single inhibitory concentration, either 100 or 200 µM
(depending upon solubility), using the malachite green assay we previously developed to
monitor PurK activity.130 This assay is a discontinuous assay and measures the free
phosphate concentration in a system. To compare inhibitory activity with the enzyme
substrate ATP, adenine and adenosine were used as positive controls. Compounds 1 and
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4 weakly inhibited PurK from A. clavatus whereas 2 and 3 were completely inactive at the
concentrations tested. Compound 1 also exhibited weak inhibitory effect against PurK from
E. coli. The enzymatic reaction time was optimized for different ATP concentrations to
ensure the reaction stays in the linear range, and the assay was used for PurK kinetics with
varied ATP concentration, while holding the concentration of AIR fixed. Steady state kinetics
of 1 against PurK from E. coli confirmed that it is competitive with ATP and has a Ki of 255
µM (Figure 9). These results validate that 1 binds to the ATP site of PurK as expected.
Table 4. Activity of BC inhibitors against PurK.
# Structure

Conc. RA%

RA%

(µM)

PurKAsp PurKE.coli

1

200

43

83

2

100

101

102

3

200

97

101

4

200

82

--

Adenine

200

91

91

Adenosine

200

53

53

-- Not tested.
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Figure 9. Lineweaver-Burke plot of 1 against PurKE. coli using the malachite green assay.
The concentration of 1 (µM) is listed to the right of the graph.
2.2 Computation studies suggested optimization positions
While we expected that the BC inhibitors would not be as potent against PurK, we were
puzzled by the ~250,000-fold weaker inhibitory activity of these inhibitors against PurK.
Using a computational binding model generated by superimposition of the ATP-grasp
regions of BC and PurK, we could propose theories explaining the decreased activity and
potential positions for structural modifications to attempt to improve activity. We also
examined the structures to identify the potential reasons why pyridopyrimidine 1 inhibited
PurK from A. clavatus better than that from E. coli. Four X-ray structures were used in model
generation: BC in complex with biotin, bicarbonate, ADP and Mg (PDB: 3G8C), BC in
complex with pyrido[2,3-d]pyrimidine inhibitor 11 (PDB: 2V58), PurKAsp in complex with AIR,
ADP and Mg (PDB: 3K5I), and PurKE. coli in complex with ADP and Mg (PDB: 1B6S).
First, BC and PurKAsp in complex with ADPs were aligned to check for topological
similarities. Chain A from each structure was used in the study. The sequences of ATPgrasp domains for BC and PurK were selected based on previous literature119 and selected
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sequences are shown in Figure 11. The structural alignment (selection to selection) was
carried out using PyMOL. Root mean square deviation (RMSD) in the aligned regions was
1.609 Å (Figure 10). The distances between the 6-NH2 and 2’-OH of the two aligned ADPs
are 1.1 Å and 1.5 Å, respectively. The key fingerprint residues in the ATP-binding sites are
also aligned (Figure 10) and the ADP binding interactions are highly similar (Figure 12).

Figure 10. Alignment of BC (PDB: 3G8C, green) and PurKAsp (PDB: 3K5I, cyan). The square
highlights the ATP-grasp domain. Figure generated using PyMOL.

Figure 11. Alignment and key fingerprint residues in the BC and PurKAsp ATP-grasp site.
Residues in bold are conserved or similar residues involved in ATP binding.
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Figure 12. 2-D illustration of the ATP binding interactions in BC (left) and PurKAsp (right).
This diagram was generated using the ligand interaction plot as generated MOE.
After confirmation of the structural similarities between the ATP-grasp domains of BC
and PurKAsp, the X-ray structures of BC in complex with a pyrido[2,3-d]pyrimidine inhibitor
11 (PDB: 2V58) was aligned to PurKAsp (PDB: 3K5I). RMSD in the aligned ATP-grasp
regions was 2.01 Å. This direct structural superimposition resulted in the 6-phenyl and 2NH2 of the pyrido[2,3-d]pyrimidine clashing with the C-domain of PurKAsp (Figure 13, left).
Energy minimization of the system resulted in a slight shift of the inhibitor (RMSD = 0.3 Å)
to avoid the clashes and generate additional interactions with the protein (Figure 13, right).

Figure 13. 2-D illustration of the pyrido[2,3-d]pyrimidine inhibitor 11 binding interactions
with the ATP-binding site of PurKAsp (PDB: 3K5I). Left: direct structure superimposition of
BC and PurKAsp. Right: Energy minimization of inhibitor 11 and PurKAsp.
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This ligand interaction diagram (Figure 13 right) thus forms the hypothetical binding
model for pyrido[2,3-d]pyrimidines binding to PurK. A couple of assumptions are made with
this model and its use. First, the weaker inhibitory activity of 1 against PurK compared to 11
against BC was not due to the dibromo substitutions on the 6-phenyl ring. Thus, the binding
model of 11 in the ATP-site of PurK represents 1 in the same place. (This assumption was
later proved correct in section 2.3.2.) Second, the pyrido[2,3-d]pyrimidine compound binds
in the same location and orientation in the ATP-site of PurKAsp as in the ATP-site of BC.
Without direct structure evidence, it is difficult to evaluate the accuracy of this assumption.
Despite the hypothetical nature of the model, it reveals some information regarding how
the pyrido[2,3-d]pyrimidine compounds interact within the ATP-site of PurKAsp. First, the key
residues that contribute to the adenine-binding in the ATP-site also play important roles in
binding with pyrido[2,3-d]pyrimidines (Figure 14). This makes sense considering pyrido[2,3d]pyrimidine is a nitrogen-containing heterocycle similar to adenine. Ala184 contributes a
H-bond donor to both the N-1 in adenine and the N-3 in pyrido[2,3-d]pyrimidine. Glu181 and
Lys182 provide H-bond acceptors to the 6-NH2 and 2-NH2 in adenine and pyrido[2,3d]pyrimidine, respectively. Lys146 donates H-bonds to the N-7 in adenine and N-1 and N8 in pyrido[2,3-d]pyrimidine. Among these four residues, Lys146 and Glu181 are conserved
fingerprint residues among all ATP-grasp enzymes. Although Lys182 is not conserved
among the enzymes of the ATP-grasp family in general, BC happens to possess a lysine
residue at the corresponding position, Lys202.
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Figure 14. 2-D illustration of the proposed binding orientation of pyrido[2,3-d]pyrimidine
overlapping with ADP in the ATP-site of PurKAsp. Interactions with inhibitors were shown in
green, while interactions with ADP were shown in red.
Second, despite the proposed six H-bond interactions between pyrido[2,3-d]pyrimidine
with the adenine-binding regions in the ATP-site of PurKAsp, few interactions were found
between either the ribose or the phosphate binding domains and the pyrido[2,3-d]pyrimidine.
In fact, we believe the limited interactions between these domains and the compound could
explain the large difference in activity of the pyrido[2,3-d]pyrimidines between BC and
PurKAsp. In BC, stacking interactions are found between His236 and His438 with the
substituted phenyl ring of the compound, and key hydrophobic interactions are also found
between this ring and Ile437 (Figure 15). In the Pfizer study of pyrido[2,3-d]pyrimidines
inhibiting BC160, a I437T mutant renders 11 more than 112-fold less active compared to the
wild-type enzyme (IC50 of 560 nM vs 5 nM) while a H438P mutant results in a more than
32-fold decrease in activity (IC50 160 nM vs 5 nM). In PurKAsp, the residue corresponding to
His236 is Ser214, and other than an analogous H-bond acceptor toward 7-NH2, no
corresponding stacking or hydrophobic interaction with the 6-phenyl ring was identified.
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PurKAsp is also shorter in its C-terminus compared to BC (Figure 16) and thus there is a loss
of the analogous hydrophobic contacts between the enzyme and the substituted phenyl ring.
The decreased length of the C-terminus, in turn, makes the ATP-binding site more spacious
in PurKAsp resulting in a decrease in shape complementarity between the inhibitor and the
binding pocket.

Figure 15. 2-D illustration of the pyrido[2,3-d]pyrimidine inhibitor 11 binding interactions
with the ATP-binding site of BC (PDB: 2V58).

I437

Figure 16. Crystal structural superimposition of PurK (pdb: 3K5I, green) and BC (pdb: 2V58,
yellow) with pyridopyrimidine 11 in the binding site. The orange circle highlights the
additional C-terminus of BC, and the arrow points to the PurK C-terminus end.
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A similar method was applied to search for the potential explanations of the relatively
poor inhibitions of pyrido[2,3-d]pyrimidine against PurKE.

coli

compared to PurKAsp. A

structural alignment was conducted between BC and PurKE. coli (RMSD 7.10 Å) and PurKAsp
with PurKE. coli (RMSD 5.46 Å). There were a few features that were noted in this comparison.
First, the ATP-site of PurKE. coli is more open than PurKAsp (Figure 17) resulting in a greater
loss of shape complementarity. Second, Trp183 in PurKAsp could contribute to a stacking
interaction with the heterocycle core in pyrido[2,3-d]pyrimidine. The corresponding residue
in PurKE. coli is Gly155 which lacks the ability for π-stacking (Figure 18). Finally, despite the
poor predictive outcome of the calculated binding energy, forcefield calculations indicated
that the calculated affinity for the system was -5.5 kcal/mol, worse than that of 11 and
PurKAsp. Due to the poor inhibition against PurKE. coli, pyrido[2,3-d]pyrimidines are less ideal
hits for antibacterial than antifungal drug development. All further activities were measured
against PurKAsp only.

Figure 17. Surfaces of the ATP-site for PurKE. coli (left) and PurKAsp (right). Molecular
surfaces are colored by atom color with blue for nitrogen, red for oxygen, yellow for sulfur
and grey for the carbon backbone.
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Figure 18. Crystal structural superimposition of PurKAsp (pdb: 3K5I, green) and PurKE. coli
(pdb: 3ETJ, cyan) with pyridopyrimidine (purple) aligned in the ATP-site. The PurKAsp
residue W183 could form stacking interaction with the heterocycle, while correspondingly
G155 resides in PurKE. coli.
The hypothetical binding model suggests further regions on the pyrido[2,3-d]pyrimidine
that could be modified to improve the activity. The model shows that there are extensive
hydrogen bonding interactions of the pyrido[2,3-d]pyrimidine heterocycle with residues in
the adenine position of the ATP-site; however, there are no obvious interactions between
the molecule and the protein within the ribose and triphosphate binding sites. This
suggested that modifications of the pyrido[2,3-d]pyrimidine at the 6-phenyl and 7-amine
positions might generate interactions with amino acids in the ribose and triphosphate sites
leading to pyrido[2,3-d]pyrimidine analogs with higher potency (Figure 19).
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Figure 19. Modification strategy.
2.3 Ribose-binding position (R1) modifications
2.3.1 Synthesis
Based on the model from the structural alignment with BC, the 6-phenyl group sits in
the ribose binding site. Thus, we prepared a series of compounds in which various
substitutions on the 6-position (R1 in Scheme 3) were generated. Synthesis of these agents
(5-23) was conducted by condensation of aldehyde 1b and nitriles to make pyrido[2,3d]pyrimidine derivatives with various groups at the 6-phenyl position (Scheme 3). Nitriles
with an aliphatic R1 were used for compounds 5 to 8 whereas substituted benzyl nitriles
were used for compounds 9 to 20, and nitriles in which R1 contained of heterocycles were
used for compounds 21 to 23.
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Scheme 3. Synthesis of pyrido[2,3-d]pyrimidines with various substitutions at the 6phenyl position. Reagents and conditions: (a) NaH, EtO(CH2)2OH, reflux, 4 h, 11-84%.
2.3.2 Biological evaluations
We examined a series of substituted 6-phenyl analogs at a single concentration (200
µM) using the malachite green PurK assay. For analogs displaying better inhibition than 1,
IC50 values were determined using the malachite green assay as well as a secondary
PK/LDH coupled PurK assay. This assay couples PurK to pyruvate kinase (PK) and lactate
dehydrogenase (LDH) and use changes in the absorption of NADH as a measure of ATP
consumption.
Three groups of variances were explored at the R1 position. The 6-phenyl was first
replaced by smaller substitutions (compound 5-8), due to a lack of obvious interactions
between the phenyl and PurKAsp. Each compound displayed weaker activity than the parent
agent. This implies that the 6-phenyl group may have unrecognized hydrophobic or
aromatic interactions or that it may help to orient the pyrido[2,3-d]pyrimidine heterocycle
into the adenine site. Indeed, minimization of molecular models of 5 indicate that there is a
substantial loss of interaction of the pyridopyrimidine with the adenine site due to movement
of 5 into the ribose binding pocket. We subsequently explored different substitutions on the
phenyl ring. Small substitutions at the 2 and 6 positions improved activity whereas large
groups decreased activity. Notably, the most active BC inhibitor, compound 11, only
exhibited 23% inhibition at 200 uM against PurKAsp and was worse than the parent
compound 1. This is interesting since 11 is a potent inhibitor of BC and this reemphasizes
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the difference among the ATP-grasp domains of enzymes within the same superfamily.
Substitutions at the 3 and 5 positions decreased activity significantly, except for the diol
substitutions, 14. This compound nearly inactivated PurKAsp at 200 uM, and subsequent
studies indicated an IC50 of 14 µM, a nearly 12-fold improvement from 1. The PK/LDH
coupled PurK assay was used to investigate the inhibition kinetics of 14. This study
indicated that 14 is competitive with ATP and has a Ki of 7.9 ± 1.6 µM against PurKAsp
(Figure 20). This activity increase offered by polar substitutions fit well with the hypothetical
binding model in which 6-phenyl sits in the ribose-binding site. Finally, we tested several
heterocycles and found that the phenyl ring appears to be the optimal option.
Table 5. Ribose position (R1) modifications.

#

R1

RA%

IC50

IC50

200 µM

Malachite

PK-LDH

green assay

assay

1

43

167±16

97±16

5

73

-

-

6

98

-

-

7

64

-

-

8

58

-

-

9

21±2

41±7

38±9
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10

24±1

40±11

58±9

11

77

-

-

12

71

-

-

13

117 (100 µM)

-

-

14

3

14±2

15±1

15

75

-

-

16

47

-

-

17

88 (100 µM)

-

-

18

NA

-

-

19

58±7

-

-

20

78±4

-

-

21

65±8

-

-
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22

51±5

-

-

23

75±4

-

-

Figure 20. Lineweaver-Burke plot of 14 against PurKAsp using the PK/LDH coupled PurK
assay. The concentration of 14 (in µM) is listed to the right of the graph. The experiment
was done at an AIR concentration of 25 µM.
2.4 Phosphate-binding position (R2) modifications
2.4.1 Synthesis
Two types of derivatives were explored at the phosphate (R2) position, N-alkylation (or
O-alkylation) and urea substitutions. These two groups were selected based on

two

reasons: synthetic feasibility and improved activity in other ATP-utilization enzymes, such
as kinases165-171. N-alkylation (24-35) and O-alkylation (36, 37) were achieved through the
critical intermediate 1e, 7-chloro-6-phenylpyrido[2,3-d]pyrimidin-2-amine. To achieve this
intermediate, the amine group of compound 1 was first hydrolyzed to the alcohol (1c) under
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acidic condition followed by chlorination using thionyl chloride. Once the chloropyridopyrimidine (1e) was obtained, the chlorine atom was readily displaced by either
amines (24-35) or alcohols (36, 37) (Scheme 4). Urea substitutions (38-50) were introduced
by direct reaction of the amines with isocyanate under basic conditions (Scheme 5).

Scheme 4. Synthesis of pyrido[2,3-d]pyrimidines with various N/O-alkylations at the 7-NH2
position. Reagent and conditions: (a) 8 M HCl, reflux, 24 h, 62%; (b) SOCl 2, DMF, CH2Cl2,
mw, 45 ºC, 1 h, 78%; (c) 95 % EtOH, reflux, 8 h, 57%; (d) DIPEA, DMF, 100 ºC, 45%; (e)
MeOH, reflux, 95%.

Scheme 5. Synthesis of pyrido[2,3-d]pyrimidines with various ureas at the 7-NH2 position.
Reagent and conditions: (a) NaH, DMF, r.t., 12h, 15-42%.
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2.4.2 Biological evaluations.
Based on the hypothetical model, the 7-NH2 points to the triphosphate binding site. Two
types of derivatives were explored at this position, N-alkylation (or O-alkylation) and urea
substitutions. These two groups were selected based upon synthetic feasibility and their
abilities to improve inhibition in other ATP-utilizing enzymes. Activities were measured as
described in the previous section.
For alkylation derivatives, cyclic (24-29), chain (30-35) and two O-alkylates (36, 37)
were explored. In the cyclic group, decreasing ring size improved activity indicating that
there is a small hydrophobic pocket at this location. Moderate activity increases were
achieved by the pyrrolidine (27) and cyclopropane (29) substitutions. Significant
improvement in activities were reached in the chain group (30-35). Simply decreasing the
polarity by one or two small alkyl substitutions (30-33) improved the activity 2-4-fold which
indicated the existence of a small hydrophobic pocket. A polar group at the end of this alkyl
chain also improved activity with a 3-carbon length (34) showing better activity than a 2carbon one (35). No significant change in activity was achieved by the O-alkylated
compounds, 36 and 37.
All the urea substitutions decreased activity and led to significant solubility issues. This
was surprising given their wide utilization in kinases inhibitors. Again, these differences
suggest the fundamental uniqueness in the ATP-binding sites of the ATP-grasp proteins
versus the protein kinases.
Table 6. Phosphate position (R2) modifications.

R2

RA%

IC50

IC50

40

200 µM

phosphate

PK-LDH

assay

assay

1

43

167±16

97±16

24

42±2 (100

75±15

81±3

µM)
25

36

-

-

26

43±3

116±12

-

27

31±2

90±5

68±3

28

48±5

-

-

29

25±1

-

-

30

18±1

39±2

33±5

31

21±1

-

-

32

38±3

69±7

71±9

33

21±1

42±4

-

34

19±1

24±5

37±2

35

35±1

91±10

-

36

46

-

-
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37

69±5 (100

-

-

µM)
38

--

-

-

39

65 (50 µM)

-

-

40

76 (50 µM)

-

-

41

83

-

-

42

88 (26 µM)

-

-

43

90 (50 µM)

-

-

44

69 (100 µM)

-

-

45

--

-

-

46

86 (26 µM)

-

-

47

69

-

-

48

70

-

-

42
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49

88

-

-

50

86

-

-

2.5 Double modifications
2.5.1 Synthesis
When we decided to combine both the R1 and R2 modifications to make the double
modified pyrido[2,3-d]pyrimidines, we first tried reactions similar to those listed in Scheme
4.

The

analogous

critical

intermediate

to

1e

was

7-chloro-6-(3,5-

dimethoxyphenyl)pyrido[2,3-d]pyrimidin-2-amine. Unfortunately, this initial approach failed
to give this intermediate presumably due to the instability of methoxy groups under acidic
conditions (Scheme 6). In fact, even the first hydrolysis reaction of converting the amine to
the alcohol group gave a majority of mono-demethylated product.

Scheme 6. The failed synthesis for the key intermediate of the double modified compounds.
Reagent and conditions: (a) 8 M HCl, reflux, 3 h, 21%.
After retrosynthetic analysis, we decided to investigate a different route. Instead of
assembling the pyrido[2,3-d]pyrimidines from the pyrimidine ring as in the previous
schemes, we set out to make the pyridine ring first (Scheme 7).
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The critical intermediate in this new synthetic route is 2,6-difluoro-5-iodonicotinaldehyde,
7c. This intermediate contains three handles needed for the synthesis of the final product.
Compound 7c contained a 2-fluorine and 3-aldehyde which enables cyclization with
guanidine to yield the pyrimidine, a 5-iodine which is necessary for aryl-aryl coupling via a
Suzuki reaction, and a 6-fluorine which enables N-substitutions. The only published protocol
for the synthesis of 7c was a patent method which produced the compound from
commercially available 2,6-difluoro-3-pyridinecarboxaldehyde172. Unfortunately, details in
the patent were limited which led to difficulty with the iodination reaction (step b in Scheme
7). Ultimately, we found that after generating the anion by LDA deprotonation, the iodine
solution needed to be added slowly during a span of at least 2 hours to ensure a consistent
and optimum yield.
After obtaining the critical intermediate 7c, we tried the subsequent three reactions
toward the final products: cyclization, Suzuki reaction and N-substitution reaction.
Compound 7c failed to undergo direct Suzuki coupling presumably due to the interference
of the aldehyde. The cyclization reaction on 7c also failed likely because of competition
reactions at the two fluorines in the molecule.
Gaining

inspiration

difluoropyridines

with

from

the

chemoselective

benzylamine173,

we

reactions

tried

to

of
react

3-substituted-2,67c

with

3-

(dimethylamino)propylamine directly and obtained 7d in a reasonable yield. No reaction at
the 2-position or Schiff base were observed. This intermediate 7d readily underwent
cyclization followed by Suzuki coupling to give a series of double-modified compounds (5157).
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Scheme 7. Synthesis of pyrido[2,3-d]pyrimidines with double modifications. Reagents
and conditions: (a) triethyl orthoformate, PTSA, EtOH, reflux, 18 h, 83%; (b) I 2, LDA, THF,
-78 ºC , 2 h, 96%; (c) HCl, THF/H2O, r.t., 4 d, 96%; (d) 3-(dimethylamino)propylamine,
K2CO3, DMSO, r.t., 2 h, 78%; (e) guanidine nitrate, TEA, MeCN, mw, 150 ºC, 1 h, 33%;
(f) Pd(PPh3)4, Na2CO3, MeCN/DMF/H2O, 90 ºC, 6 h, 45-68%.
2.5.2 Biological evaluations.
Examination of compounds with modifications in the ribose (R1) or triphosphate (R2)
binding sites resulted in compounds (14 and 34) with improved activity. Thus, it was logical
to explore agents in which both sites were substituted with the best substituent. Together
with the exact combination of 14 and 34, we also explored a few other substituents on the
phenyl ring. Due to synthetic limitations, only one N-alkylation substituent was explored at
the R2 position.
Double-modified compounds indeed combined the activity gain of each modification.
Interestingly, cyclohexene substituted 55 has similar activity with phenyl 34, while
cyclohexane 57 decreased activity. Both indoles, 53 and 54, improved activity with 53 better
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than 54. The most active compound 56 – directly merging 14 and 34 – has an IC50 of 1.7
µM. This is 100-fold improvement from the parent hit 1, and the most active ATP-site PurKAsp
inhibitor to date.
To confirm binding affinity, we developed a thermal shift assay128, 174-175 for PurK. To
develop the condition of thermal shift assay for PurK, 1 mM ADP was used as the positive
control to optimize the buffer type, concentration, pH and salt additives. The condition in
which ADP achieved the largest shift of the protein melting point was selected as the
optimized condition. We examined a range of buffers including 50 mM Tris (pH 8.0), 50 mM
HEPEs (pH 8.0), 50 mM sodium phosphate (pH 8.0), 50 mM MOPS (pH 8.0) and 50 mM
MES (pH 6.5). MES was selected and further tested for optimal pH from 5.5 to 8.0 in 0.5 pH
interval. A pH 6.0 was selected followed by the optimization of the MES concentration.
Three different concentrations were tested, 20 mM, 50 mM and 100 mM, and 20 mM
achieved the maximum thermal shift for ADP. Finally, NaCl was tested as an additive (0, 50
mM and 250 mM) and it was found that no salt achieved the best melting curve. The
optimized condition was 20 mM MES buffer, pH 6.0. Under this condition, 1 mM ADP
achieved a 7.2 ± 0.5 ºC shift of the PurK melting point. Using the optimized condition, we
validated the binding of 1 and 56 (Figure 21) giving a Kd of 117.2 ± 53.9 µM and 9.0 ± 1.7
µM. The low accuracy for the Kd of 1 is likely because of the inability to measure melting at
higher concentrations due to solubility issues. This prevents the reaching of a plateau
reducing the accuracy of the curve fit.
Table 7. Double modifications.

#

R1

R2

RA%

IC50

46

200 µM

phosphate
assay

34

19±1

24±5

51

72±4

-

52

38±2

-

53

6±0.4

6.1±0.6

54

12±1

-

55

20±1

-

56

3.1±0.2

1.7±0.2

57

32±2

-

58

86 (26

-

µM)
59

28 (100

-

µM)
60

60 (26
µM)

-
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Figure 21. Binding affinity of compound 1 and 56 against PurKAsp as measured by the thermal
shift assay.
2.6 1,6-naphthyridines and 1,8-naphthyridines
2.6.1 Synthesis
Previously, we have discovered that pyrido[2,3-d]pyrimidine weakly inhibited PurKAsp,
and through modifications of the 6-phenyl and 7-NH2 positions we were able to obtain
compounds with better inhibitory activity. To study the functions of the aza atoms of the
pyridopyrimidine moiety in interacting with PurKAsp, we synthesized two small groups of
compounds containing 1,6-naphthyridine and 1,8-naphthyridine, respectively (Figure 22).
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The knowledge of the heteroatoms’ contributions in affinity not only extends the SAR of the
pyridopyrimidine core, but also helps to evaluate the computational binding model between
PurKAsp and the pyridopyrimidine compounds.

Figure 22. Structures of pyrido[2,3-d]pyrimidine, 1,6-naphthyridine and 1,8-naphthyridine.
Both 1,6-naphthyridines and 1,8-naphthyridines were made using similar approaches
as that for pyrido[2,3-d]pyrimidines in Scheme 1. In short, the heterocycle was obtained by
a condensation reaction between a molecule possessing both an amine and an aldehyde
group ortho to the amine and different acetonitriles (Scheme 8 and 9).
The precursor for 1,6-naphthyridines, 4,6-diaminonicotinaldehyde (8c), was made from
the commercially available 2-amino-1,1,3-propenetricarbonitrile using a three-step
published method176-178. Condensation reactions between 4,6-diaminonicotinaldehyde and
different acetonitriles resulted in the corresponding 1,6-naphthyridines (Scheme 8). The
precursor for 1,8-naphthyridines, 2,6-diaminonicotinaldehyde (9a), was made from pyridine2,6-diamine using a published method179, and similar condensations with acetonitriles gave
the desired1,8-naphthyridines (Scheme 9). In both cases, we chose R1 groups based upon
the activity of the parent pyridopyrimidine compounds outlined in previous tables.
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Scheme 8. Synthesis of 1,6-naphthyridines. Reagents and conditions: (a) HBr/HOAc, r.t.,
18 h, 79%; (b) H2, 10% Pd/C, NaHCO3, MeOH, 15 psi, 6 h, 42%;(c) Ra-Ni, 98-100%
HCOOH, reflux, 24 h, 34%; (d) NaH, EtO(CH2)2OH, reflux, 2-24 h, 13-96%.

Scheme 9. Synthesis of 1,8-naphthyridines. Reagents and conditions: (a)NaOH, CHCl3,
ethanol, reflux, 18 h, 29%; (b) NaH, EtO(CH2)2OH, reflux, 3-7 h, 19-87%.
2.6.2 Functions of the aza atoms in pyridopyrimidine
The activity of the 1,6-naphthyridines and 1,8-naphthyridines against PurKAsp were
evaluated at a single concentration of 200 µM using the malachite green phosphate assays
(Table 8). Compared with the parent pyridopyrimidines, all 1,8-naphthyridines completely
lost activity indicating that the N-3 forms crucial interaction within the PurKAsp active site.
The 1,6-naphthyridines generally possessed small to modest reductions in activity
compared to the parent compounds. Compounds bearing the 2,6-F and 3,5-OCH3
substituents were essentially as active as the pyridopyrimidines while other substitutions
generally lost about 20% of their potency. This data suggests that unlike N-3, N-1 is not
critical for binding to the enzyme.
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Table

8.

1,6-naphthyridines

(left),

1,8-naphthyridines

(middle)

and

the

parent

pyridopyrimidines (right).
#

RA%

#

#

62

68±2

67

98±7

1

43±2

63

57±2

68

92±6

10

24±1

64

14±1

-

-

9

21±2

65

77±5

69

84±4

19

58±7

66

77±4

70

94±3

15

75±4

2.7 Development of binding models to PurKAsp for pyrido[2,3-d]pyrimidine inhibitors
In this thesis, we have identified a group of pyrido[2,3-d]pyrimidine containing
compounds as PurKAsp ATP-competitive inhibitors. Modifications were made at the N-1, N3, C-6, and C-7 positions and the resulting compounds were utilized to determine a
structure-activity relationship (SAR). To understand the structural basis for their potency
and selectivity and to rationalize the observed SAR to benefit future structural-based
optimization efforts, we were interested in developing a computational binding model of
these compounds against PurK. Two different approaches were taken to generate models.
The first took advantage of the structural similarities among the ATP-grasp domain proteins
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and the extensive ligand: enzyme crystal structures for some of these enzymes, while the
second utilized docking to generate hypothetical binding models.
2.7.1 Binding model based on structural alignment
The construct of this model was described in section 2.2 (Figure 23). This model was
built from structural superimposition of the crystal structures of PurK and BC. Based on the
interactions found in this model, we decided to explore structural modifications of the 6phenyl and 7-NH2 positions. Each position gave a full range of SAR with both improved and
decreased activity ranging at least two magnitudes in the differences in IC50. This change
in SAR verified the suitability of these two positions for medicinal chemistry optimization. In
this section, we evaluate whether this model could explain the SAR obtained from our
studies.

Figure 23. The hypothetical binding model generated by structural superimposition of
PurKAsp (pdb: 3K5I) and BC (pdb: 2V58).
First, we examined whether the proposed H-bond interactions in the model are
supported by the SAR observed by the two groups of naphthyridine compounds. Based on
the model, N-3 forms a critical interaction with Ala184, while N-1 and N-8 share an
interaction with Lys146. Due to synthetic limitations, we did not convert the N-8 in
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pyrido[2,3-d]pyrimidine to C to make a group of quinazolines; however, we expected the
quinazolines would have similar activity to 1,6-naphthyridines. These results indicate that
N-3 forms a critical binding interaction while the bifurcated nature of the H-bond to Lys146
indicates that removal of the N-1 was not detrimental to the activity. This suggests that the
H-bond interaction to Lys146 is not critical for binding to the enzyme.
We next wished to test the validity of the binding model based on the SAR of the 6phenyl and 7-NH2 modified compounds. The calculated binding affinity of the compounds
were plotted against the percent residual activity to determine whether the calculated
binding affinity based upon the model could accurately predict the potency of the inhibitors.
PurKAsp was prepared using the QuickPrep function in MOE which checks the structure
for completeness and protonation state. Non- active-site water molecules, defined as waters
farther than 4.5 Å away from ligand, were deleted. Residues that are 8 Å away from ligand
were fixed during minimization. Forcefield energy minimization was terminated when the
RMS gradient fell below 0.1 kcal/mol/Å. Each compound was placed into the model using
the same orientation and location as 11, and energy minimization was performed to
calculate potential affinity180.
Figure 24 summarized the calculated affinity (kcal/mol) vs. experimental %RA of all
compounds that were tested at 200 µM. Linear regression was performed resulting in an R2
of 0.22, suggesting that the predictive ability of the binding model is poor. The binding model
also failed to predict that compound 14 and 34 were the most active derivatives at the C-6
and N-7 positions respectively. However, when the data was separated by the modification
position and indicated in different colors, the calculated affinity was generally the largest for
C-6 modifications (orange) and smallest for the double modifications (blue) with the N-7
modifications (grey) in between. This general trend agrees with their relative activity shown
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in the experimental test. With a few exceptions (9, 10, and 14), the C-6 modifications did
not improve activity, while most N-7 non-urea modifications gave more active compounds,
and the double modified compounds were able to combine the activity gain of each position.
Most N-7 urea modifications had solubility limitations at 200 µM, and therefore were not
included in the graphic analysis. However, an examination of the calculated binding affinity
of the urea substituted compounds indicated that these compounds were poor binders due
to clashes with PurKAsp, a result supported by experimental evidence.
140
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R² = 0.2159
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Figure 24. Correlation of calculated affinity (kcal/mol) vs. experimental %RA. Different
modifications are represented by different colors: orange for C-6 modifications, grey for
N-7 modifications, and blue represents the double modifications
There are several potential reasons why the calculated affinity is in poor correlation with
experiment %RA. First, the original assumptions made in the model (pyrido[2,3-d]pyrimidine
binds the active site of PurK the same as in BC, and all pyrido[2,3-d]pyrimidines bind in the
ATP-site in the same orientation as the parent compound 11) are inaccurate. Second, the
binding energy calculations do not consider the issue of desolvation energy upon binding
to the enzyme. Third, the protein structure is rigid in the forcefield calculation and fails to
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represent the real protein structure. Fourth, there could be structural water molecules that
are necessary for binding and these are not included in the model or the energy calculations.
2.7.2 Binding model based on docking studies
While the binding model generated by structural alignments could provide some
information on the interactions between the ligand and the enzyme, the model gave a poor
correlation between the calculated binding energy and the observed potency. While other
factors explained in the previous section could provide an explanation for the poor
performance, we felt that the initial assumptions of the model could be incorrect. Namely,
we were concerned that the pyrido[2,3-d]pyrimidine might not bind to the ATP-site of PurK
in the same orientation as in BC and consequently, we were also worried that different
derivatives of the compounds may adopt different binding orientations within the more open
ATP-binding site of PurK. Studies on the ATP-site inhibitors of kinases suggested that
derivatives of the same scaffolds could indeed bind the active site in different orientations181.
To eliminate the bias of the orientation provided by the alignment to the structure of the
ligand:BC complex, we conducted docking studies to explore other binding models.
Docking studies were done using chain A of PurKAsp in complex with AIR, ADP and Mg
(PDB: 3K5I). The crystal structured was corrected and prepared using the MOE Structure
Preparation application, the hydrogen bond network was optimized through Protonate 3D,
and charges were calculated via Partial Charges. Since pyrido[2,3-d]pyrimidine was
confirmed as an ATP-competitive inhibitor in our kinetics analysis, the binding site was
specified as the ATP-binding site.
Before docking of the inhibitors was conducted, studies using the natural substrate ADP
was done to refine the docking parameters. A Triangle Matcher placement method180 with
London dG scoring function was applied with a maximum of 30 poses returned. The
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structures generated by the placement method was further refined by either rigid receptor
or induced fit with GBVI/WSA dG as the final scoring function, and the final output was 5
poses. Both the rigid receptor and the induced fit refinement methods gave similar final
poses, and for simplicity considerations, rigid receptor was used in the remaining docking
studies. The final docking scores for the 5 output poses ranged between -11.72 to -11.31,
and RMSD between the docked poses from the original ligand ranged between 1.07 to 2.12
Å (Table 9). All five docked poses process similar interactions with the enzyme as observed
in the crystal structure with ADP (Figure 25). Thus, these docking parameters were utilized
in the exploration of binding models of the pyrido[2,3-d]pyrimidines.
Table 9. The docking scores and RMSD values of the 5 output poses of ADP. The ranking
was determined by the scoring function.
#

S

RMSD (Å)

1

-11.7250

1.0668

2

-11.6590

1.9729

3

-11.5331

1.7365

4

-11.4915

1.0982

5

-11.3173

2.1226

1
2

56

3

4

5
Figure 25. 2-D illustration of the 5 docked ADP poses interacting with the ATP-binding site
of PurKAsp (PDB: 3K5I). Red: original ADP from X-ray structure. Green: docked ADP.
To examine the binding of ligands, the parent inhibitor 11 was docked into the ATP-site
of PurKAsp according to the method described above. The crystal structure of 11 came from
it complexed with BC (PDB: 2V58). The 3D conformation of the ligand went through the
conformation-check in MOE with no changes. The final scores for the 5 output poses ranged
between -3.86 to -2.08, and RMSD between the docked 11 from the original ligand ranged
between 0.92 to 2.07 Å (Table 10). All five docked poses differ from each other with the
fourth pose (ranked by score) most resembling the binding model built from the structural
alignment (Figure 26).
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Table 10. The docking scores and RMSD values of the 5 output poses of inhibitor 11. The
ranking was determined by the scoring function.
#

S

RMSD (Å)

1

-3.8590

1.6131

2

-3.5136

1.6142

3

-3.3461

2.0675

4

-2.7844

0.9206

5

-2.0818

1.3119

1

2

3

4

58

5
Figure 26. 2-D illustration of the 5 docked 11 poses interacting with the ATP-binding site of
PurKAsp (PDB: 3K5I). Red: binding orientation from structural alignment. Green: docked
pose. The enzyme was positioned to catch maximum interactions with the docked poses
instead of the one from structural alignment.
The SAR generated by 1,6-naphthyridine and 1,8-naphthyridine was used to evaluate
the likelihood of the docked poses. The SAR of these two groups of compounds was
weighed more heavily than the C-6 and N-7 derivatives because they are direct changes of
the pyrido[2,3-d]pyrimidine core scaffolds while others are changes on side chains. Based
on the SAR of 1,6-naphthyridine and 1,8-naphthyridine, N-1 and N-3 should form critical
interactions with PurKAsp with the N-3 interaction being indispensable. Among the five
docked poses, poses 3, 4, and 5 displayed the importance of N-1; and pose 1 and 5
indicated that N-3 is significant. Given the fact that pose 4 is similar to the orientation
generated by the structural alignment, we believe that docking pose 4 and 5 explains the
SAR the best and should be given more consideration in future studies.
Finally, all the C-6 and N-7 non-urea derivatives were docked into the ATP-site of
PurKAsp using the same parameters. The crystal structure of 11 from it complexed with BC
(PDB: 2V58) formed the basis of all the derivative conformation, and changes in the side
chains were manually built into 11. The 3D conformations and charges of the ligands
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manual input were then calculated and corrected by MOE’s Conformation Import. This
function returns the lowest energy conformation of each derivative by decomposing each
ligand into constituent overlapping fragments, performing stochastic conformational search
on each fragment, and then assembling the fragments into unique conformers. Five docked
poses were returned for each derivative. All the poses were further analyzed by the Protein
Ligand Interaction Fingerprints (PLIF) tool in MOE. The PLIF is a method for summarizing
the interactions between ligands and proteins using a fingerprint scheme180.

Figure 27. Population display of the PLIF generated by all the docking poses of the C-6
and N-7 non-urea derivatives.
Figure 27 is a population display of the generated fingerprint. The columns for each
residue represents the number of potential modes of interaction between this residue and
the ligands. If there is more than one column for a residue, there is more than one pose that
interacts with that residue. When we examine the residues interacting with the pyrido[2,3d]pyrimidine core scaffold, the four residues in the adenine binding pocket are Lys146,
Glu181, Lys182, and Ala184. Among these four residues, each possess at least two poses,
suggesting there are two dominant poses for the pyrido[2,3-d]pyrimidine core in all
derivatives. A close examination revealed that these two dominant poses were represented
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by the pose 4 and 5 in Figure 26, suggesting that the binding orientations generated by
unbiased docking studies matched with that derived by SAR analysis.
Since pose 4 is the same as that generated by the structural alignment to BC, detailed
examination of this model was given in were given in section 2.7.1. Pose 5 was examined
in the original PurKAsp structure. Rather than binding in the adenine-site, the pyrido[2,3d]pyrimidine core sat in the ribose-phosphate site of the ATP-binding site in pose 5, and the
6-phenyl occupied the adenine binding site (Figure 28). Compared with the orientation
generated by structural alignment, pose 5 was able to predict that the 3’, 5’-OH substituted
6-phenyl and 3-(dimethylamino) propyl substituted 7-amino could form more interactions
with PurKAsp (Figure 29), hence increasing activity. Pose 5 has its limitations as well. For
example, this pose fails to predict the activity gain by small hydrophobic groups at 7-N.

Figure 28. 2-D illustration of the docking pose 5 of pyrido[2,3-d]pyrimidine overlapping
with ADP in the ATP-site of PurKAsp. Interactions with inhibitors were shown in green,
while interactions with ADP were shown in red.
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Figure 29. 2-D illustration of the docking pose 5 of 54 in PurKAsp.
The docking studies remove the assumption that pyrido[2,3-d]pyrimidine binds the ATPsite of PurKAsp in the same orientation as it binds BC. However, with no direct structural
information, the possibilities for different derivatives possessing various orientations still
hold. We should keep this in mind when using computational models to design future
modifications.
In summary, structural alignments and docking were used to generate potential binding
orientations of pyrido[2,3-d]pyrimidine in the ATP-site of PurKAsp. The two most likely poses
were identified with the heterocycle core sitting in the adenine site and ribose phosphate
site, respectively. Both poses provide valid explanations for the SAR of changes on the
heterocycle core. The second pose in which the pyrido[2,3-d]pyrimidine occupies the
ribose-phosphate site is partially explained by the observed side chain SAR. Both poses
should be given equal considerations when designing new pyridopyrimidine analogs.
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CHAPTER 3 CONCLUSIONS
Taking inspiration from the nanomolar inhibitors described against BC, we tested four
different known scaffolds against PurK from two different microbial species. Only one
compound, 1, containing a pyrido[2,3-d]pyrimidine core, weakly inhibits PurKAsp with an IC50
of 167 μM, however this compound is inactive against PurKE. coli. Kinetic assays confirmed
that 1 is an ATP-competitive inhibitor. With the guidance of computational modeling, we
examined analogs of this lead agent with substituents in the ribose and triphosphate binding
sites within the ATP-site. The ribose position modification, compound 14, has an IC50 of 14
µM, a 12-fold increase in activity. Additional studies revealed a compound (34), with
modification in the phosphate binding site with an IC50 of 24 µM. Combining these two
substitutions gave compound 56 with an IC50 of 1.7 µM, a 100-fold improvement in potency
from the lead agent. This compound is the most potent ATP-binding site inhibitor against
PurKAsp described to date. The compounds reported here will serve as starting point to
develop anti-fungal agents targeting the de novo purine biosynthesis pathway.
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CHAPTER 4 FUTURE DIRECTIONS
4.1 General future directions
No antimicrobial studies were conducted for these compounds in our study. Considering
pyrido[2,3-d]pyrimidines inhibited PurK from A. Clavatus better than that from E. coli, an
antifungal study is warranted. However, the compounds described here still resemble
inhibitors of BC and thus, further studies are needed to determine the BC activity of these
agents. Even if BC activity is limited, any potential antifungal activity must still be validated
as the result of inhibiting PurK instead of BC. This could be accomplished by the use of CO2
rescue studies182 which has been shown to be a selective rescue for PurK inactivity. For the
long-term goal of antimicrobial drug development, a dual target inhibitor against both PurK
and BC could be an interesting approach since this could reduce the chance of resistance
development.
To improve specificity and potency, continued structural modifications to obtain more
potent compounds is a necessary. In the current study, computational models were used to
suggest structural modifications. Although improved compounds were obtained, our models
are hypothetical at best and are not based upon experimental evidence. To obtain direct
binding information, X-ray analysis of protein:ligand complexes are needed. Fortunately,
PurK has been crystallized121, 139, although no structure of an inhibitor:PurK complex has
been described in the literature.
4.2 Apply covalent inhibitor strategy to increase target specificity and selectivity
Other approaches to increase activity could also be explored, including the use of
covalent strategies. Traditionally, covalent inhibitors were often associated with a lack of
target specificity and increased off-target and side effects183. However, the recent
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successes with quiescent affinity labels used in protease184 and kinase inhibitors185 have
reinvigorated interest in covalent inhibitors among many drug discovery researchers186-187.
Affinity labels are molecules that have a chemically reactive functional group and will
undergo chemical reaction to form a covalent bond with another molecule that processes a
complementary group188. A popular example of an affinity label used as drugs is omeprazole.
Omeprazole is converted to a more reactive sulphenamide under the acidic environment in
the stomach. The sulphenamide reacts with a cysteine residue of the gastric H+/K+ ATPase
to inhibit the enzyme activity and therefore is used to treat acid reflux disease 188. Other
examples of quiescent affinity labels in medical uses include aspirin and penicillin, and they
both labels a serine residue in their target proteins.
More recent successes for covalent inhibitors as drugs are the applications in the
protease189-190 and kinase191 inhibitors. Added Michael acceptors onto the original noncovalent inhibitors have led to agents that target cysteine residues in their target proteins
rendering the protein inactive. Examples of these inhibitors are shown in Figure 30.

Figure 30. Examples of covalent inhibitors. The Rhinovirus 3C protease inhibitor189-190 (a)
and the epidermal growth factor receptors (EGRF) protein kinase inhibitor191 (b). The
boxes indicate the Michael acceptor.
Inspired by these results, we were interested to see if we could apply the covalent
inhibitor strategy by adding a covalent warhead to our reversible PurK inhibitor pyrido[2,3d]pyrimidines. We will discuss our preliminary results in the following sections.
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4.2.1 Using the cysteine modifier to probe cysteine functions in PurKAsp
A close examination of the ATP-binding site of PurKAsp revealed that Cys266 has the
potential to be targeted by quiescent affinity labels. Cys266 is in a β-sheet of the C1-domain
of PurKAsp, and it is involved in the binding of the ribose phosphate part of the ATP (Figure
31). Cys266 is about 40% conserved and involved in the binding of ATP in the ATP-grasp
enzymes. Other than cysteine, a more common residue at this location is asparagine.
Among the PurKs from different species, cysteine is conserved within all species of
Aspergillus,

Histoplasma

capsulatum,

Paracoccidioides

brasiliensis,

and

Pseudogymnoascus. Asparagine is found from E. coli, S. aureus, Candida, and
Cryptococcus. This divergence would increase the selectivity of the potential covalent
inhibitors targeting PurK.

Figure 31. Interaction of Cys266 with ADP in PurKAsp (pdb: 3K5I).
A key question is whether Cys266 is reactive and thus could be targeted by covalent
inhibitors. Given this question, we conducted studies aimed at examining whether N-methyl
maleimide, a known cysteine reactive probe, would inhibit PurKasp by modifying Cys266.
4.2.2 Probe the cysteine function using N-methyl maleimide
The effect of N-methyl maleimide on PurK was measured by the PK/LDH coupled assay.
Various concentrations of N-methyl maleimide were incubated with PurK from different
organisms. Different effects of N-methyl maleimide were observed against PurKAsp and
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PurKE.

coli.

For PurKAsp, activity was inhibited, and the progress curves showed a time-

dependent curvature. For PurKE. coli, N-methyl maleimide appeared to have no effect (Figure
32). To further confirm that N-methyl maleimide directly inhibits PurKAsp in a time dependent
fashion, N-methyl maleimide was pre-incubated with PurKAsp, and after 20 min, 93.5% of
the enzymatic activity was lost. The curvature observed from N-methyl maleimide inhibiting
PurKAsp could result from several factors including N-methyl maleimide reacting with the
enzyme or reagents in the system, or the induction of conformational changes of the
enzyme. Using the negative result from PurKE. coli, we can rule out the possibilities that Nmethyl maleimide reacts with reagents in the assay.

Figure 32. PK/LDH coupled PurK reaction was initiated with PurK at time 0 and the
conversion of NADH to NAD+ was measured at 340 nm.
4.2.3 N-FITC maleimide binds PurKAsp and PurKE. coli covalently
Based on the reactive nature of maleimide with the thiol of cysteines, it is logical to
believe that N-methyl maleimide inhibits PurK by covalent modification. To confirm this, NFITC maleimide was incubated with PurKAsp and PurKE. coli at room temperature for 30 min.
Excess N-FITC maleimide was removed by spin columns with 10K molecular weight cutoff.
The enzymes were examined by reducing SDS-PAGE and fluorescent bands of both
PurKAsp and PurKE. coli (Figure 33) were observed indicating that N-FITC maleimide modified
both enzymes covalently.
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Figure 33. FITC-maleimide covalently labeled both PurKAsp (45 kDa) and PurKE. Coli (40 kDa).
1. PurKAsp + FITC-maleimide; 2. PurKAsp + DMSO; 3. PurKE. Coli + FITC-maleimide; 4. PurKE.
Coli +

DMSO.

4.2.4 ATP protected PurKAsp from the time-dependent inhibition of N-methyl
maleimide
The fact that FITC-malemide also binds to PurKE. coli indicates that there are multiple
cysteines that can be modified by the malemide reagents. Thus, it is unclear whether the
inhibition of PurKAsp is due to inhibition of Cys266. To investigate the cause of the timedependent inhibition of PurKAsp, kinetic studies were carried out to see if ATP could protect
PurKAsp from the inhibition of N-methyl maleimide. If the modification of PurKAsp by N-methyl
maleimide could be prevented by the binding of ATP, increasing the ATP concentration
should result in a decrease in the observed rate of inactivation (kobs). The PK/LDH assay
was used to monitor the progress curve of PurKAsp with a fixed 100 µM concentration of Nmethylmaleimide while various concentrations of ATP were added. The resulting curves
were fitted using Equation 1 to determine kobs for each experiment. A decrease kobs versus
increase in ATP concentration indicates that ATP protects PurKAsp from N-methyl maleimide
inhibition (Figure 34). This suggests that the inactivation of PurKAsp occurs because of a
modification of a cysteine near the ATP-binding site.

68

𝑣𝑖
[𝑃 ] =
[1 − exp(−𝑘𝑜𝑏𝑠 ∗ 𝑡)]
𝑘𝑜𝑏𝑠

Eq. 1

Figure 34. PK/LDH coupled PurK reaction was initiated with PurK at time 0, and the
conversion of NADH to NAD+ was measured at 340 nm. A fixed concentration of 100 µM
N-methylmaleimide was presented in all reactions with increased concentrations of ATP
as shown in the left. The progression curves were fitted to equation 1 to generate kobs.
The secondary plot of kobs vs. [ATP]/Km (Km[ATP] = 60 µM142) was shown to the right and
demonstrates a clear decrease in rate as the ATP concentration increases.
4.2.5 The time-dependent inhibition of N-methyl maleimide against PurKAsp is not due
to the modification of Cys266, but Cys216
To further narrow the cause of the time-dependent inhibition, two mutant proteins
C266S and C266A were made. We anticipated that both proteins would be active yet would
not display inhibition in the presence of N-methyl maleimide. Both proteins indeed retained
their catalytic activity. However, to our surprise, treatment with N-methyl maleimide resulted
in time-dependent inhibition for both mutant proteins (Figure 35). This interesting, yet
unexpected result, generated a few hypotheses. First, N-methyl maleimide does not
covalently modify Cys266. Although Cys266 is an exposed residue, there is no direct
evidence to indicate that it is modified. A second hypothesis is that N-methyl maleimide
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covalently labels Cys266, yet this modification does not influence the enzymatic activity. To
explore these hypotheses, we conducted additional experiments aimed at identifying the
cysteine residue responsible for the inhibition of PurKAsp.
A close examination of all of the cysteines in PurKAsp revealed that there are five
cysteines (Figure 36). The remaining four cysteines are not conserved among ATP-grasp
enzymes. Other than Cys266, Cys216 is the closest to the active sites. Therefore we made
a mutant protein, C216S, and like the C266 mutants, this mutant also retained catalytic
activity. To our great surprise, N-methyl maleimide did not inhibit the activity of the C216S
mutant (Figure 35). It is challenging to form a plausible hypothesis as for how modification
of Cys216 results in inhibition of the enzyme. The residue does not appear to interact with
any substrate, although the sulfur atom is about 7.5 Å away from the free phosphate in the
crystal structure (Figure 37). Cys216 is not a conserved residue and the analogous residue
in PurKE. coli is Leu189.
These experiments showed that labeling Cys266 by N-methyl maleimide, if it does
occur, did not render PurKAsp inactive. Our original idea to add a covalent warhead in
pyrido[2,3-d]pyrimidine to target this residue requires modification.
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Figure 35. PK/LDH coupled PurK reaction was initiated with PurK (WT or mutants) at
time 0 and the conversion of NADH to NAD+ was measured at 340 nm. A fixed
concentration of 100 µM N-methylmaleimide was presented in all runs.
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Figure 36. PurKAsp (pdb: 3K5I). 5 cys, ADP, and AIR are shown in sticks.

AIR
Pi
ADP
His273

Cys216

Figure 37. The relative position of Cys216 compared to the enzymatic substrates. (This
is a preliminary figure just to show the position).
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CHAPTER 5 METHODS AND MATERIALS
5.1 Chemistry
Reactions were run in anhydrous solvents purchased from Acros and used without
further purification unless otherwise indicated. Argon was purchased from Airgas. Starting
materials were purchased from Acros, Fisher, or Sigma and used without further purification
unless otherwise indicated. Solvents used for work-ups and chromatography (methanol,
acetone, dichloromethane, chloroform, ethyl acetate and hexanes) were purchased in bulk
from Fisher.
Microwave irradiation reactions were performed using a single-mode InitiatorTM
Microwave Synthesizer from Biotage using standard Biotage vessels. Column
chromatography was carried out on silica gel (Sorbtech). Reactions were monitored by
analytical TLC (w/UV 254 nm) and visualized by UV (254 nm and 360 nm). 1H and 13C NMR
spectra were recorded on Varian 600 MHz NMR without temperature regulation. Chemical
shifts are given in ppm (δ) using tetramethylsilane (TMS) as an internal standard. Mass
spectra were recorded by Micromass LCT Premier XE instrument (Waters) with ESI/TOF.

Scheme 10. Synthesis of 7. Reagents and conditions: (a) NaH, EtOH, reflux, 24 h, 24%.
Ethyl 2,7-diaminopyrido[2,3-d]pyrimidine-6-carboxylate (7). To a solution of sodium
ethoxide prepared from NaH (4 mmol, 160 mg, 60% slurry in Hexanes) and ethanol (10 mL)
was added ethyl cyanoacetate (10 mmol, 1.66 mL). The mixture was stirred under argon at
room temperature for 15 min. To this, 1b192 (5 mmol, 680 mg) was added and the reaction
was heated to reflux for 24 h and then cooled to room temperature. The resulting precipitate
was collected by filtration and the solid washed with water, CH3CN and Et2O, sequentially.
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Column chromatography (99/1 to 97.5/2.5 to 90/10 CH2Cl2/MeOH) gave 7 (276 mg, 1.18
mmol, yield 24%) as a white solid. TLC (90/10 CH2Cl2/MeOH, Rf = 0.38). 1H NMR (600 MHz,
DMSO-d6) δ 8.84 (1H, s, -ArH4), 8.56 (1H, s, -ArH5), 7.71 (2H, s, -NH2), 7.19 (2H, s, -NH2),
4.31 (2H, q, J = 7.1 Hz, -CH2CH3), 1.34 (3H, t, J = 7.1 Hz, -CH2CH3).

13

C NMR (150 MHz,

DMSO-d6) δ 166.3 (COO), 165.2 (C2), 163.7 (C7), 162.7 (C6), 162.1 (C7a), 143.1 (C4),
108.1 (C4a), 105.2 (C5), 61.2 (CH2), 14.6 (CH3). ES-MS [M+1] found 234.1, calculated for
C10H12N5O2 234.2.

Scheme 11. Synthesis of 6. Reagents and conditions: (a) 2 N NaOH, MeOH, reflux, 3 h,
34%.
2,7-Diaminopyrido[2,3-d]pyrimidine-6-carboxylic acid (6). A suspension of 7 (267
mg, 1.1 mmol) in 2 N NaOH (10 mL) was heated at reflux for 3 h. The suspension became
clear after heating for 15 min and remained clear. Water was removed in vacuo and the
solid was recrystallization from water to give 6 as the sodium salt (pale yellow solid, 90 mg,
0.4 mmol, yield 34%). TLC (90/10 CH2Cl2/MeOH, Rf = 0). 1H NMR (600 MHz, DMSO-d6) δ
10.14 (1H, d, J = 6.1 Hz, -NH2), 8.57 (1H, s, -ArH4), 8.23 (1H, s, -ArH5), 6.94 (1H, d, J =
6.1 Hz, -NH2), 6.53 (2H, s, -NH2). 13C NMR (150 MHz, CD3OD) δ 172.0 (COOH), 169.7 (C2),
163.4 (C7), 163.1 (C8a), 162.0 (C4), 140.9 (C5), 112.7 (C6), 106.6 (C4a). ES-MS [M-1]
found 204.1, calculated for C8H6N5O2 204.0.
General method for cyclization (1, 8-13, 15-22, 62-66, 71)193. The reactions were run
in 0.2 – 1 mmol scale. 2-Ethoxyethanol was dried over K2CO3, distilled and stored over
molecular sieves. To a solution of sodium 2-ethoxyethoxide (4 eq), prepared from NaH and
2-ethoxyethanol, was added various acetonitriles (2 eq). The mixture was stirred under
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argon at room temperature for 30 min to 3 h. To the reaction, 1b192 (8c for 1,6naphthyridines) (1 eq) was added and the reaction was heated at reflux for 4 h. The reaction
was cooled to room temperature, poured into cold water and chilled at 4 °C overnight. The
resulting precipitate was collected by filtration and sequentially washed with water, CH3CN
and Et2O. The solids were dried in vacuo to give 1, 8-13, and 15-22, 71. Compound 1, 5, 913, 15-17 was synthesized following a literature method161. Compound 19, 21, and 22 were
made based on a patent194. Compound 20 was made based on a patent195. Naphthyridines
62-66 were made based on the literature196-198. NMR analysis of the literature compounds
agreed with the published values and thus are not listed below.
2-Ethoxyethyl 2,7-diaminopyrido[2,3-d]pyrimidine-6-carboxylate (8). Brown solid
(42%). TLC (90/10 CH2Cl2/MeOH, Rf = 0.42). 1H NMR δ 8.86 (1H, s, -ArH4), 8.54 (1H, s, ArH5), 7.69 (2H, s, -NH2), 7.20 (2H, s, -NH2), 4.38 (2H, d, J = 4.3 Hz, -COOCH2CH2), 3.70
(2H, d, J = 4.7 Hz, -COOCH2CH2), 3.51 (2H, q, J = 7.0 Hz, -OCH2CH3), 1.13 (3H, t, J = 7.0
Hz, -OCH2CH3).

C NMR (150 MHz, DMSO-d6) δ 166.2 (COO), 163.2 (C2), 161.7 (C7),

13

157.1 (C7a), 145.1 (C4), 135.2 (C5), 115.7 (C6), 109.1 (C4a), 68.2 (CH2CH2), 67.2
(CH2CH3), 63.2 (CH2CH2), 14.6 (CH3). ES-MS [M+1] found 278.1, calculated for C12H16N5O3
278.3.
6-(Naphthalen-2-yl)pyrido[2,3-d]pyrimidine-2,7-diamine (18). Yellow solid (yield
69%). TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.54). 1H NMR (600 MHz, DMSO-d6) δ 8.70
(1H, s, -ArH4), 8.05 – 7.95 (5H, m, -NapH), 7.77 (1H, s, -ArH5), 7.61 – 7.52 (4H, m, -NapH,
-NH2), 6.74 (2H, s, -NH2).

C NMR (150 MHz, DMSO-d6) δ 163.9 (C2), 161.5 (C7), 160.9
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(C8a), 160.8 (C4), 137.4 (C5), 135.0 (C2’), 133.7 (C4a’), 132.8 (C8a’), 128.9 (C5’), 128.5
(C8’), 128.0 (C3’), 128.0 (C4’), 127.3 (C7’), 126.8 (C6’), 126.7 (C1’), 121.0 (C6), 109.2 (C4a).
ES-MS [M+1] 288.0, calculated for C17H14N5 288.1.
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6-(1-Trityl-1H-imidazol-4-yl)pyrido[2,3-d]pyrimidine-2,7-diamine (71). The solid and
the CH3CN fraction were combined and concentrate to dryness in vacuo. Column
chromatography (0 to 4% MeOH in DCM to 94.5/5/0.5 to 92/7.5/0.5 CH2Cl2/MeOH/NH4OH)
gave 71 (yield 45%) as a dark brown solid. TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf =
0.17). 1H NMR (600 MHz, CDCl3) δ 8.57 (1H, s, -ArH4), 7.71 (1H, s, -ArH5), 7.52 (1H, d, J
= 1.3 Hz, -imidH2’), 7.42 – 7.35 (10H, m, -TrtH), 7.22 (1H, d, J = 1.4 Hz, -imidH5’), 7.21 –
7.17 (7H, m, -TrtH, -NH2), 5.12 (2H, s, -NH2).

C NMR (150 MHz, CDCl3) δ 162.7 (C2),
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161.2 (C7), 160.0 (C8a), 159.7 (C4), 141.9 (Ph), 138.1 (C4’), 138.0 (C2’), 131.8 (C5), 129.7
(Ph), 128.3 (Ph), 128.2 (Ph), 118.5 (C5’), 113.1 (C6), 109.3 (C4a), 75.9 (C). ES-MS [M+1]
470.0, calculated for C29H24N7 470.2.

Scheme 12. Synthesis of 14. Reagents and conditions: (a) BBr3, CH2Cl2, 0 ºC to r.t., 24
h, 43%.
5-(2,7-Diaminopyrido[2,3-d]pyrimidin-6-yl)benzene-1,3-diol (14). A solution of 15192
(148 mg, 0.5 mmol) in anhydrous CH2Cl2 (3 mL) was cooled to 4 ºC in an ice bath. A solution
of BBr3 in CH2Cl2 (5 mmol, 1M, 5 mL) was added dropwise to the reaction and the reaction
was stirred overnight. Water (2 mL) was added to quench the reaction and the precipitate
was collected by filtration and dried in vacuo. Column chromatography (78/20/2
CH2Cl2/MeOH/NH4OH) gave 14 (58 mg, 0.21 mmol, yield 43%) as a dark brown solid. TLC
(4/1 EtOAc/MeOH, Rf = 0.16). 1H NMR (600 MHz, DMSO-d6) δ 9.43 (2H, s, 2×-OH), 8.64
(1H, s, -ArH4), 7.58 (1H, s, -ArH5), 6.64 (2H, s, -NH2), 6.26 (2H, d, J = 2.1 Hz, -PhH2’, 6’),
6.24 (1H, t, J = 2.1 Hz, -PhH4’).

C NMR (150 MHz, DMSO-d6) δ 162.4 (C2), 162.1 (C4),

13
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160.0 (C7), 159.4 (C3’), 156.5 (C8a), 137.9 (C1’), 137.2 (C5), 121.9 (C6), 108.0 (C4a),
107.2 (C2’), 103.0 (C4’). ES-MS [M+1] found 270.1, calculated for C13H12N5O2 270.1.

Scheme 13. Synthesis of 23. Reagents and conditions: (a) TFA, r.t., 1 h, 83%.
6-(1H-Imidazol-4-yl)pyrido[2,3-d]pyrimidine-2,7-diamine (23). A suspension of 71
(47 mg, 0.1 mmol) in TFA (1 mL) was stirred in a sealed vial at room temperature for 1 h.
The reaction was concentrated to dryness in vacuo and the residue purified by column
chromatography (94.5/5/0.5 to 78/20/2 CH2Cl2/MeOH/NH4OH) to give 23 (19 mg, 0.08 mmol,
yield 83%) as a yellow solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.07). 1H NMR (600
MHz, DMSO-d6) δ 12.46 (1H, s, -imidNH), 8.57 (1H, s, -ArH4), 8.08 (1H, s, -ArH5), 7.82
(1H, d, J = 1.2 Hz, -imidH2’), 7.69 (1H, d, J = 1.3 Hz, -imidH5’), 6.65 (2H, s, -NH2). 13C NMR
(150 MHz, CDCl3) δ 163.7 (C2), 158.2 (C7), 167.0 (C8a), 150.7 (C4), 139.1 (C4’), 138.8
(C2’), 135.8 (C5), 118.5 (C5’), 118.1 (C6), 109.3 (C4a). ES-MS [M+1] found 228.1,
calculated for C13H12N5O2 228.1.

Scheme 14. Synthesis of pyrido[2,3-d]pyrimidines with various substitutions at the 7-NH2
position. Reagents and conditions: (a) neat amine, reflux, 6-12 h, 34-68 %.
General method for N7-substitution (27-29, 31-35). A suspension of 1e194 (51 mg, 0.2
mmol) in various neat amines (1-3 mL, 60-150 eq) was refluxed for 6 to 12 h, and the excess
amines were removed in vacuo. Column chromatography of the residue gave 27-29, 31-35
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in moderate yields. Compound 27 was made following a patent method194. NMR analysis
of 27 was consistent with the literature analysis.
N7-Cyclopentyl-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine

(28).

Column

chromatography (1 to 3% MeOH/CH2Cl2 to 94/5/1 CH2Cl2/MeOH/NH4OH) gave 28 as a
yellow solid (30 mg, yield 50%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.57). 1H NMR
(600 MHz, CDCl3) δ 8.59 (1H, s, -ArH4), 7.53 – 7.47 (2H, m, -Ph), 7.47 – 7.41 (2H, m, -Ph),
7.43 – 7.37 (2H, m, -ArH5, -Ph), 5.53 – 5.41 (2H, m, -NH2), 5.22 (1H, d, J = 7.5 Hz, -NH),
4.78 – 4.69 (1H, m, -CH), 2.18 – 2.09 (2H, m, -CH2), 1.66 – 1.58 (4H, m, -CH2CH2-), 1.39 –
1.29 (2H, m, -CH2). 13C NMR (600 MHz, CDCl3) δ 163.1 (C2), 161.3 (C7), 159.8 (C4), 159.4
(C8a), 136.5 (C1’), 135.0 (C5), 129.4 (C3’), 128.9 (C2’), 128.4 (C4’), 123.1 (C6), 109.2
(C4a), 52.6 (CH), 33.2 (CH2), 23.6 (CH2). ES-MS [M+1] 306.2, calculated for C18H20N5 306.2.
N7-Cyclopropyl-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine

(29).

Column

chromatography (1 to 3% MeOH/CH2Cl2) gave 29 as a yellow solid (22 mg, yield 40%). TLC
(94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.49). 1H NMR (600 MHz, CDCl3) δ 8.64 (1H, s, ArH4), 7.52 – 7.45 (3H, m, -ArH5, -Ph2’), 7.46 – 7.40 (1H, m, -Ph4’), 7.39 – 7.34 (2H, m, Ph3’), 5.39 – 5.28 (3H, m, -NH, -NH2), 3.10 (1H, tq, J = 3.7, 7.3 Hz, -CH), 0.94 – 0.85 (2H,
m, -CH2), 0.52 – 0.45 (2H, m, -CH2). 13C NMR (600 MHz, CDCl3) δ 163.0 (C2), 161.2 (C8a),
160.9 (C7), 160.1 (C4), 136.3 (C1’), 135.1 (C5), 129.4 (C3’), 128.9 (C2’), 128.5 (C4’), 123.0
(C6), 109.6 (C4a), 24.7 (CH), 7.5 (CH2). ES-MS [M+1] 278.0, calculated for C16H16N5 278.1.
N7,N7-Diethyl-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine

(31).

Column

chromatography (1 to 3% MeOH/CH2Cl2 to 94/5/1 CH2Cl2/MeOH/NH4OH) gave 31 as a
yellow solid (36 mg, yield 68%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.43). 1H NMR
(600 MHz, CDCl3) δ 8.65 (1H, s, -ArH4), 7.52 (1H, s, -ArH5), 7.45 – 7.39 (4H, m, -Ph2’, 3’),
7.38 – 7.30 (1H, m, -Ph4’), 5.55 (2H, s, -NH2), 3.39 (4H, q, J = 7.0 Hz, 2×-CH2CH3), 1.04
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(6H, t, J = 7.1 Hz, 2×-CH2CH3). 13C NMR (600 MHz, CDCl3) δ 163.1 (C2), 162.5 (C7), 160.2
(C4), 159.7 (C8a), 140.5 (C1’), 138.8 (C5), 128.8 (C3’), 127.6 (C2’), 127.3 (C4’), 124.7 (C6),
109.7 (C4a), 44.2 (CH2), 13.0 (CH3). ES-MS [M+1] 266.1, calculated for C17H20N5 266.1.
6-Phenyl-N7-(prop-2-yn-1-yl)pyrido[2,3-d]pyrimidine-2,7-diamine

(32).

Column

chromatography (1 to 3% MeOH/CH2Cl2) gave 32 as a yellow solid (36 mg, yield 67%). TLC
(94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.25). 1H NMR (600 MHz, CDCl3) δ 8.66 (1H, s, ArH4), 7.55 – 7.48 (3H, m, -ArH5, -Ph), 7.48 – 7.40 (3H, m, -Ph), 5.54 (2H, s, -NH2), 5.38
(1H, t, J = 5.1 Hz, -NH), 4.44 (2H, dd, J = 2.6, 5.1 Hz, CH2), 2.22 (1H, t, J = 2.5 Hz, -C≡CH).
C NMR (600 MHz, CDCl3) δ 163.1 (C2), 160.8 (C8a), 160.4 (C4), 158.8 (C7), 135.9 (C1’),
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135.6 (C5), 129.5 (C3’), 129.0 (C2’), 128.6 (C4’), 122.9 (C6), 109.5 (C4a), 80.1 (C≡CH),
71.6 (C≡CH), 31.4 (CH2). ES-MS [M+1] 276.3, calculated for C16H14N5 276.1.
N7-Methyl-6-phenyl-N7-(prop-2-yn-1-yl)pyrido[2,3-d]pyrimidine-2,7-diamine

(33).

Column chromatography (1st 1 to 3% MeOH/CH2Cl2; 2nd 67 to 100% EtOAc/hexane) gave
33 as a yellow solid (20 mg, yield 34%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.41).
H NMR (600 MHz, CDCl3) δ 8.74 (1H, s, -ArH4), 7.66 (1H, s, -ArH5), 7.49 – 7.42 (4H, m, -

1

Ph2’, 3’), 7.41 – 7.33 (1H, m, -Ph4’), 5.52 (2H, s, -NH2), 4.21 (2H, d, J = 2.4 Hz, CH2), 2.88
(3H, s, -CH3), 2.18 (1H, t, J = 2.5 Hz, CH). 13C NMR (600 MHz, CDCl3) δ 163.2 (C2), 162.6
(C7), 160.8 (C4), 159.3 (C8a), 139.6 (C1’), 139.2 (C5), 129.0 (C3’), 127.7 (C2’), 127.5 (C4’),
124.1 (C6), 110.2 (C4a), 79.4 (-C≡CH), 72.2 (-C≡CH), 41.7 (CH2), 38.9 (CH3). ES-MS [M+1]
290.2, calculated for C17H16N5 290.1.
N7-(3-(Dimethylamino)propyl)-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine

(34).

Column chromatography (3% MeOH/CH2Cl2 to 94/5/1 to 89/10/1/ CH2Cl2/MeOH/NH4OH)
gave 34 as a yellow solid (28 mg, yield 43%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf =
0.18). 1H NMR (600 MHz, CDCl3) δ 8.55 (1H, s, -ArH4), 7.55 (1H, t, J = 4.4 Hz, -NH), 7.49
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– 7.43 (2H, m, -Ph), 7.46 – 7.35 (4H, m, -ArH5, -Ph), 5.52 (2H, s, -NH2), 3.75 – 3.69 (2H,
m, -NHCH2CH2CH2), 2.32 (2H, d, J = 5.8 Hz, -NHCH2CH2CH2), 1.86 (6H, s, -N(CH3)2), 1.68
(2H, p, J = 5.9 Hz, -NHCH2CH2CH2). 13C NMR (600 MHz, CDCl3) δ 163.1 (C2), 161.4 (C8a)
160.2 (C7), 159.5 (C4), 136.9 (C1’), 134.7 (C5), 129.2 (C3’), 128.9 (C2’), 127.9 (C4’), 123.8
(C6), 109.0 (C4a), 59.2 (-NHCH2CH2CH2), 44.9 (-N(CH3)2), 42.6 (-NHCH2CH2CH2), 24.8 (NHCH2CH2CH2). ES-MS [M+1] 323.2, calculated for C18H23N6 323.2.
N7-(2-(dimethylamino)ethyl)-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine
Column

chromatography

(1st

1

to

3%

MeOH/CH2Cl2 to

94/5/1

to

(35).
89/10/1

CH2Cl2/MeOH/NH4OH; 2nd 94/5/1 CH2Cl2/MeOH/NH4OH) gave 35 as a yellow solid (30 mg,
yield 48%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.13). 1H NMR (600 MHz, CDCl3)
δ 8.59 (1H, s, -ArH4), 7.51 – 7.45 (3H, m, -ArH5, -Ph), 7.45 – 7.39 (3H, m, -Ph), 6.08 (1H,
t, J = 4.8 Hz, -NH), 5.42 (2H, s, -NH2), 3.67 (2H, td, J = 4.8, 6.0 Hz, -NHCH2CH2), 2.49 (2H,
t, J = 6.0 Hz, -NHCH2CH2), 2.17 (6H, s, -N(CH3)2). 13C NMR (600 MHz, CDCl3) δ 163.1 (C2),
161.3 (C7), 159.8 (C4), 159.7 (C8a), 136.4 (C1’), 135.0 (C5), 129.2 (C3’), 128.9 (C2’), 128.3
(C4’), 123.4 (C6), 109.3 (C4a), 57.4 (-NHCH2CH2), 45.0 (-N(CH3)2), 38.9 (-NHCH2CH2). ESMS [M+1] 309.1, calculated for C17H21N6 309.2.

Scheme

15.

Synthesis

of

24

and

25.

Reagents

and

conditions:

(a)

2,4-

dimethoxybenzylamine, Cs2CO3, dioxane, reflux, 4 h, 40%; (b) BBr3, CH2Cl2, 0 ºC to r.t., 24
h, 20%.
N7-(2,4-Dimethoxybenzyl)-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine

(24).

A

suspension of 2,4-dimethoxybenzylamine (33 µL, 0.22 mmol) and Cs2CO3 (215 mg, 0.66
mmol) in dioxane (3 mL) was refluxed for 45 min before adding 1e (51 mg, 0.2 mmol). The
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reaction was continued to reflux for 10 h. The reaction solids were removed by filtration and
the filtrate was dried in vacuo. Column chromatography of the filtrate (0 to 5% MeOH in
CH2Cl2 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 24 (31 mg, yield 40%) as a brown solid. TLC
(4/1 EtOAc/MeOH, Rf = 0.66). 1H NMR (600 MHz, CDCl3) δ 8.58 (1H, s, -ArH4), 7.48 – 7.37
(6H, m, -ArH5, -Ph), 7.27 (1H, d, J = 8.9 Hz, -Ph), 6.44 – 6.39 (2H, m, -Ph), 6.01 (1H, t, J =
5.5 Hz, -NH), 5.47 (2H, s, -NH2), 4.77 (2H, d, J = 5.5 Hz, -CH2), 3.77 (3H, s, -CH3), 3.67
(3H, s, -CH3). 13C NMR (150 MHz, CDCl3) δ 163.0 (C2), 161.2 (C7), 160.4 (C4’’), 159.8 (C4),
159.5 (C8a), 158.7 (C2’’), 136.5 (C1’), 135.0 (C5), 130.6 (C6’’), 129.2 (C3’), 129.0 (C2’),
128.3 (C4’), 123.4 (C1’’), 118.7 (C6), 109.3 (C4a), 103.8 (C5’’), 98.6 (C3’’), 55.4 (CH3), 55.0
(CH3), 41.4 (CH2). ES-MS [M+1] found 388.2, calculated for C22H22N5O2 388.2.
4-(((2-Amino-6-phenylpyrido[2,3-d]pyrimidin-7-yl)amino)methyl)benzene-1,3-diol
(25). The synthesis of compound 25 followed the same procedure as for compound 14.
Column chromatography (0 to 3% MeOH in CH2Cl2 to 94.5/5/0.5 CH2Cl2/MeOH/NH4OH)
gave 25 (yield 20%) as a brown solid. TLC (4/1 EtOAc/MeOH, Rf = 0.23). 1H NMR (600
MHz, DMSO-d6) δ 11.06 (1H, d, J = 6.3 Hz, -OH), 9.13 (1H, s, -OH), 8.67 (1H, s, -ArH4),
7.62 (1H, s, -ArH5), 7.54 – 7.39 (5H, m, -Ph), 7.20 (1H, t, J = 6.1 Hz, -NH), 6.99 (1H, d, J =
8.2 Hz, -Ph5’), 6.86 (2H, s, -NH2), 6.19 (1H, d, J = 2.5 Hz, -Ph4’), 6.15 (1H, dd, J = 2.4, 8.1
Hz, -Ph2’), 4.35 (2H, s, -NH2).

C NMR (150 MHz, DMSO-d6) δ 163.2 (C2), 161.2 (C7),
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158.5 (C8a), 158.4 (C4’’), 155.4 (C2’’), 150.8 (C4), 136.4 (C1’), 135.0 (C5), 130.6 (C6’’),
129.2 (C3’), 129.0 (C2’), 128.3 (C4’), 115.4 (C1’’), 110.8 (C6), 109.3 (C4a), 108.8 (C5’’),
103.4 (C3’’), 41.4 (CH2). ES-MS [M+1] found 359.9, calculated for C20H18N5O2 360.1.
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Scheme 16. Synthesis of 26. Reagents and conditions: (a) piperidin-4-ol, KOtBu, dioxane,
reflux, 4 h, 29%.
1-(2-Amino-6-phenylpyrido[2,3-d]pyrimidin-7-yl)piperidin-4-ol (26). A solution of
piperidin-4-ol (21 mg, 0.2 mmol) and KOtBu (0.22 mmol, 25 mg) in dioxane (5 mL) was
stirred under argon at room temperature for 1 h. To the reaction, 1e (51 mg, 0.2 mmol) was
added and the reaction was heated to reflux for 4h. The resulting solids were removed by
filtration and the solution was dried in vacuo. Column chromatography (1% MeOH in CH2Cl2
to 94.5/5/0.5 CH2Cl2/MeOH/NH4OH) of the residue gave 26 as a yellow solid (19 mg, yield
29%). TLC (94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.18). 1H NMR (600 MHz, DMSO-d6) δ
8.80 (1H, s, -ArH4), 7.79 (1H, s, -ArH5), 7.54 (2H, dd, J = 1.4, 8.1 Hz, -Ph3’), 7.47 (2H, t, J
= 7.7 Hz, -Ph2’), 7.36 (1H, t, J = 7.4 Hz, -Ph4’), 6.86 (1H, s, -NH2), 4.65 (1H, d, J = 4.1 Hz,
-OH), 3.61 – 3.54 (3H, m, -CH, -piperH), 2.88 (2H, td, J = 2.8, 11.5 Hz, -piperH), 1.65 – 1.60
(2H, m, -piperH), 1.34 – 1.25 (2H, m, -piperH).

C NMR (150 MHz, CDCl3) δ 163.6 (C2),
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163.0 (C7), 160.6 (C4), 159.6 (C8a), 139.9 (C1’), 138.8 (C5), 129.1 (C3’), 127.6 (C4’), 127.2
(C2’), 124.9 (C6), 110.4 (C4a), 67.6 (-CHOH), 46.1 (-NCH2CH2), 34.0 (-NCH2CH2). ES-MS
[M+1] found 322.0, calculated for C18H20N5O 322.2.

Scheme 17. Synthesis of 30. Reagents and conditions: (a) SOCl2, DMF, CH2Cl2, mw,
70 °C, 1 h, 78%; (b) EtOH, reflux, 12 h, 57%.
N'-(7-chloro-6-phenylpyrido[2,3-d]pyrimidin-2-yl)-N,N-dimethylformimidamide
(1d)193. In a 20-mL microwave reaction vessel, a solution of 1c193 (952 mg, 4 mmol) in
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anhydrous DMF (3 mL) and freshly distilled SOCl2 ( 15 mL) was irradiated at 70 °C for 1 h
(absorbance: high). The reaction was transferred to a 250-mL round bottom flask and dried
in vacuo. The residue was dissolved in ice water and the pH was adjusted to 10 using 6 N
NaOH. After chilling at 4 °C overnight, the precipitate was collected by filtration, rinsed with
cold water and dried in vacuo to give 1d (969 mg, yield 78%) as a pale yellow solid. TLC
(9/1 EtOAc/MeOH, Rf = 0.26). 1H NMR (600 MHz, DMSO-d6) δ 9.45 (1H, s, -ArH4), 8.90
(1H, s, -ArH5), 8.45 (1H, s, -N=CH-), 7.59 – 7.45 (5H, m, -Ph), 3.24 (3H, s, -NCH3), 3.14
(3H, s, -NCH3). ES-MS [M+1] found 312.1, calculated for C16H10ClN5 312.1.
7-Chloro-6-phenylpyrido[2,3-d]pyrimidin-2-amine

(1e)193,

N7,N7-dimethyl-6-

phenylpyrido[2,3-d]pyrimidine-2,7-diamine (30) (Method 1). A mixture of 1d (2 g, 6.4
mmol) and ethanol (100 mL) was refluxed overnight. The solution was reduced to about 50
mL in vacuo and chilled at 4 °C for 5 h. The precipitate was collected by filtration. Column
chromatography (3/2 CH2Cl2/EtOAc) of the residue gave the major product 1e as the first
fraction and by-product 30 as the second fraction. Compound 1e was obtained as a bright
yellow solid (935 mg, yield 57%). TLC (4/1 hexane/EtOAc, Rf = 0.45). 1H NMR (600 MHz,
DMSO-d6) δ 9.24 (1H, s, -ArH4), 8.29 (1H, s, -ArH5), 7.55 – 7.43 (7H, m, -Ph, -NH2).
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C

NMR (150 MHz, DMSO-d6) δ 164.5 (C4), 164.2 (C2), 159.0 (C8a), 155.5 (C7), 140.5 (C5),
137.4 (C6), 130.6 (C1’), 130.0 (C3’), 128.8 (C2’), 128.6 (C4’), 113.1 (C4a). ES-MS [M+1]
found 257.1, calculated for C13H10ClN4 257.1. Compound 30 was obtained as a pale yellow
solid (326 mg, yield 19%). TLC (4/1 hexane/EtOAc, Rf = 0.08). 1H NMR (600 MHz, DMSOd6) 8.77 (1H, s, -ArH4), 7.77 (1H, s, -ArH5), 7.49 – 7.40 (4H, m, -Ph), 7.38 – 7.32 (1H, m, Ph), 6.80 (2H, s, -NH2).

C NMR (150 MHz, DMSO-d6) δ 163.1 (C2), 163.0 (C7), 160.4
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(C4), 159.6 (C8a), 140.3 (C1’), 138.8 (C5), 128.8 (C3’), 127.7 (C2’), 127.3 (C4’), 123.9 (C6),
109.8 (C4a), 41.3 (NCH3). ES-MS [M+1] found 266.1, calculated for C15H16N5 266.1.

83

N7,N7-Dimethyl-6-phenylpyrido[2,3-d]pyrimidine-2,7-diamine (30) (Method 2). In a 5mL microwave reaction vessel, 1e (51 mg, 0.2 mmol) was added to a dimethylamine/THF
solution (2 M, 2 mL, 4 mmol). The mixture was irradiated at 70 °C for 2.5 h (absorption:
poor) and the solvent was removed in vacuo. Column chromatography (94.5/5/0.5 to
78/20/2 CH2Cl2/MeOH/NH4OH) gave 30 (51 mg, yield 97%) as a yellow solid.

Scheme 18. Synthesis of 36. Reagents and conditions: (a) MeOH, DIPEA, reflux, 12 h,
80%.
7-Methoxy-6-phenylpyrido[2,3-d]pyrimidin-2-amine (36). A suspension of 1e194 (51
mg, 0.2 mmol) and DIPEA (70 µL, 0.4 mmol) in MeOH (3 mL) was refluxed for 12 h, and
then concentrated to dryness in vacuo. Column chromatography (94.5/5/0.5 to 78/20/2
CH2Cl2/MeOH/NH4OH) gave 36 (40 mg, yield 80%) as a yellow solid. TLC (4/1
hexane/EtOAc, Rf = 0.2). 1H NMR (600 MHz, CDCl3) δ 8.89 (1H, s, -ArH4), 7.86 (1H, s, ArH5), 7.60 – 7.53 (2H, m, -Ph2’), 7.49 – 7.43 (2H, m, -Ph3’), 7.43 – 7.37 (1H, m, -Ph1’),
5.49 (2H, s, -NH2), 4.15 (3H, s, -OCH3).

C NMR (600 MHz, CDCl3) δ 163.1 (C2), 158.0
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(C7), 159.6 (C8a), 148.4 (C4), 138.8 (C5), 136.3 (C1’), 128.8 (C3’), 127.5 (C2’), 127.3 (C4’),
125.9 (C6), 109.8 (C4a), 54.4 (OCH3). ES-MS [M+1] found 253.1, calculated for C14H13N4O
253.1.
General method for urea formation (38-50). To a solution of 1 (48 mg, 0.2 mmol) in
DMF (5 mL) was added 60% NaH (10 mg, 0.24 mmol). The reaction mixture was stirred at
room temperature for 1 h, followed by the addition of various isocyanates (0.24 mmol, 1.2
eq). The reaction mixture stirred at room temperature overnight and the solvent was
removed under high vacuum and the residue was directly purified by column
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chromatography (94.5/5/0.5 to 78/20/2 CH2Cl2/MeOH/NH4OH) to give 38-50 in moderate
yields. Compound 38, 39, 43-46 was made following a patent method194. Compound 4042 was made following the literature153. Compound 47-50 was made following the
literature169. NMR analysis of the literature compounds were in agreement with the literature
values and are not reported here.
2,6-Difluoro-5-iodonicotinaldehyde (7c)172. 7c was made from commercially available
2,6-difluoronicotinaldehyde

using

a

modified

procedure172.

A

solution

of

2,6-

difluoronicotinaldehyde (2.86 g, 20 mmol), triethyl orthoformate (5 mL, 30 mmol) and ptoluenesulfonic acid (380 mg, 2 mmol) in ethanol (60 mL) was heated at reflux overnight.
The solvent was removed and the residue was diluted with EtOAc and washed with sat.
NaHCO3 and brine. The organic layer was dried over MgSO4 and concentrated in vacuo.
Silica column chromatography (0 to 5% EtOAc in pet ether) gave the protected compound
7a (3.6 g, yield 83%) as a clear, colorless oil. TLC (4/1 EtOAc/Hexanes, Rf = 0.68). This
material was used in the next step. In a flame-dried 250 mL 3-neck round bottom flask, a
solution of freshly distilled diisopropylamine (3.37 mL, 24 mmol) in anhydrous THF (8 mL)
was cooled in a dry ice-acetone bath. A thermometer was inserted into the reaction to
monitor temperature. After the mixture was cooled to under -60 °C, a solution of nbutyllithium (1.5 M in hexanes) (14.4 mL, 21.6 mmol) was added dropwise through a
dropping funnel. The speed of addition was controlled so that the temperature was always
below -60 °C. The mixture was stirred at -60 °C for 5 min and warmed to room temperature
and stirred for 10 min. The mixture was recooled to -70 °C in the dry ice-acetone bath and
a solution of 7a (1.736 g, 8 mmol) in 8 mL THF was injected slowly to prevent the
temperature rising above -60 °C. The mixture was stirred at -70 °C for 90 min. To this
reaction, a solution of iodine (2.64g, 10.4 mmol) in 40 mL THF was added using a syringe
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pump (20 mL/h) over a 2 h period. After the addition of iodine, the reaction was removed
from the dry ice-acetone bath and the temperature slowly rose to room temperature. The
reaction was treated with sat. NaHSO3 (40 mL) for 60 min before diluting with 250 mL EtOAc
and washed with 1 N HCl (2×100 mL) and brine (150 mL). The organic phase was dried
over MgSO4 and concentrated in vacuo to give an oil that slowly solidified affording 7b (2.65
g, 7.7 mmol, yield 96%) as a white solid. TLC (4/1 EtOAc/Hexanes, Rf = 0.78). The final
product was obtained as follows. A solution of 7b (1.11 g, 3.2 mmol) and HCl (1 N in water,
12 mL, 12 mmol) in THF (12 mL) was added to a round-bottom flask and the flask was
sealed by septum and parafilm. The reaction was incubated at room temperature for 4 days.
The reaction was directly poured into a separation funnel and diluted with 50 mL EtOAc.
The organic layer was washed with sat. NaHCO3 followed by brine. The organic layer was
dried over MgSO4 and concentrated in vacuo. Silica column chromatography (0 to 5%
EtOAc in Hexanes) gave 7c (0.84 g, yield 96%) as a white solid. TLC (4/1 EtOAc/Hexanes,
Rf = 0.88). 1H NMR (600 MHz, CDCl3) δ 10.18 (1H, s, -CHO), 8.73 (1H, t, J = 8.1 Hz, -ArH).
C NMR (150 MHz, CDCl3) δ 183.4 (CHO), 163.7 (dd, J = 14.6, 10.2 Hz, C6), 162.0 (dd, J
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= 14.5, 3.9 Hz, C2), 152.5 (dd, J = 5.2, 2.5 Hz, C4), 117.6 (dd, J = 20.9, 5.8 Hz, C3), 71.3
(dd, J = 41.3, 5.7 Hz, C5). ES-MS [M+1] found 269.7, calculated for C6H3F2INO 269.9.
6-((3-(Dimethylamino)propyl)amino)-2-fluoro-5-iodonicotinaldehyde (7d)173. To a
reaction under argon, a solution of 7c (716 mg, 2.67 mmol) in anhydrous DMSO (20 mL)
was treated with 3-(dimethylamino)propylamine (352 µL, 2.79 mmol) and K2CO3 (735 mg,
5.34 mmol) and stirred at room temperature for 2 h. The reaction mixture was poured into
200 mL of water and chilled at 4 °C overnight. A pale-yellow precipitate was collected by
filtration and the solid was washed with cold water. The solid was re-dissolved with 5 mL
1:1 CH2Cl2 / MeOH, and the insoluble impurities were discarded. The organic solution was
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concentrated and dried in vacuo to give 7d (733 mg, 78% yield) as a pale yellow solid. TLC
(94.5/5/0.5 CH2Cl2/MeOH/NH4OH, Rf = 0.15). 1H NMR (600 MHz, CDCl3) δ 9.88 (1H, s, CHO), 8.88 (1H, s, -NH), 8.31 (1H, d, J = 9.0 Hz, -ArH), 3.61-3.58 (2H, m, NHCH2CH2CH2N), 2.56 (2H, t, J = 5.4 Hz, -NHCH2CH2CH2N), 2.31 (6H, s, -N(CH3)2), 1.811.77 (2H, m, -NHCH2CH2CH2N). 13C NMR (150 MHz, CDCl3) δ 183.6 (CHO), 165.6 (d, J =
240 Hz, C2), 159.3 (d, J = 15 Hz, C6), 147.1 (C4), 108.2 (d, J = 30 Hz, C3), 73.2 (C5), 59.4
(-NHCH2CH2CH2N), 45.4 (-N(CH3)2), 44.1 (-NHCH2CH2CH2N), 24.2 (-NHCH2CH2CH2N).
ES-MS [M+1] found 352.0, calculated for C11H16FIN3O 352.2. Note: The regioselectivity of
7d was characterized by the coupling constant (J) in 13C NMR.
N7-(3-(Dimethylamino)propyl)-6-iodopyrido[2,3-d]pyrimidine-2,7-diamine (7e)199. In
a 5-mL microwave vessel, a solution of 7d (105 mg, 0.3 mmol) in anhydrous acetonitrile (3
mL) was treated with guanidine nitrate (44mg, 0.36 mmol) and triethyl amine (101 µL, 0.72
mmol). The mixture was irradiated with stirring at 150 °C for 60 min (absorption: normal).
The reaction was subsequently transferred into a 100-mL round bottom flask and dried in
vacuo. Silica column chromatography (94.5/5/0.5 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave
7e (37 mg, yield 33%) as a brown oil. TLC (develop twice in 89/10/1 CH2Cl2/MeOH/NH4OH,
Rf = 0.09). 1H NMR (600 MHz, CDCl3) δ 8.50 (1H, s, -ArH4), 8.13 (1H, s, -NH), 8.08 (1H, s,
-ArH5), 5.29 (2H, s, -NH2), 3.75 (2H, q, J = 5.6 Hz, -NHCH2CH2CH2N), 2.59 (2H, t, J = 6.0
Hz, -NHCH2CH2CH2N), 2.35 (6H, s, -N(CH3)2), 1.87-1.83 (2H, m, -NHCH2CH2CH2N).
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C

NMR (150 MHz, CDCl3) δ 163.1 (C7), 160.9 (C2), 159.4 (C8a), 158.9 (C4), 145.3 (C5),
110.8 (C4a), 77.9 (C6), 58.9 (-NHCH2CH2CH2N), 45.4 (-N(CH3)2), 43.1 (-NHCH2CH2CH2N),
24.6 (-NHCH2CH2CH2N). ES-MS [M+1] found 373.0, calculated for C12H18IN6 373.0.
General method for Suzuki coupling (51-57)199-200. A mixture of 7e (1 eq), boronic acid
(1.1 eq), Pd(PPh3)4 (0.1 eq) and Na2CO3 (2 eq) was purged with argon three times. A
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mixture of solvents (1/0.5/0.1 CH3CN/DMF/H2O) was degassed by bubbling with argon for
10 min and the solvents were added to the solids. The reaction was heated to 90 °C for 5
h. The resulting solids were moved by filtration, and the filtrate was dried in vacuo. Column
chromatography over silica gel using the methods below gave the desired compounds, 5155.
6-(2,6-Dimethoxyphenyl)-N7-(3-(dimethylamino)propyl)pyrido[2,3-d]pyrimidine-2,7diamine (51). Column chromatography (94.5/5/0.5 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave
51 (yield 70%) as a yellow solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.45). 1H NMR
(600 MHz, CDCl3) δ 8.51 (1H, s, -ArH4), 7.36-7.34 (2H, m, -ArH5, -Ph4’), 6.87 (1H, s, -NH),
6.65 (2H, d, J = 8.4 Hz, -Ph3’, 5’), 5.36 (2H, s, -NH2), 3.71-3.68 (8H, m, -NHCH2CH2CH2N,
2×-OCH3), 2.30 (2H, t, J = 6.0 Hz, -NHCH2CH2CH2N), 1.89 (6H, s, -N(CH3)2), 1.68-1.64 (2H,
m, -NHCH2CH2CH2N).
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C NMR (150 MHz, CDCl3) δ 162.9 (C2), 161.6 (C7), 160.8 (C8a),

159.2 (C2’, C6’), 158.6 (C4), 140.0 (C5), 130.0 (C4’), 116.4 (C6), 113.0 (C4a), 109.2 (C1’),
104.1 (C3’, C5’), 59.0 (-NHCH2CH2CH2N), 55.8 (-OCH3), 44.9 (-N(CH3)2), 41.9 (NHCH2CH2CH2N), 25.2 (-NHCH2CH2CH2N). ES-MS [M+1] found 382.3, calculated for
C20H27N6O2 382.2.
6-(3,5-Dimethoxyphenyl)-N7-(3-(dimethylamino)propyl)pyrido[2,3-d]pyrimidine-2,7diamine (52). Column chromatography (94.5/5/0.5 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave
52 (yield 66%) as a yellow solid. TLC (develop twice in 89/10/1 CH2Cl2/MeOH/NH4OH, Rf =
0.47). 1H NMR (600 MHz, CDCl3) δ 8.56 (1H, s, -ArH4), 7.53 (1H, t, J = 4.2 Hz, -NH), 7.41
(1H, s, -ArH5), 6.51 (3H, s, -Ph2’, 4’, 6’), 5.37 (2H, s, -NH2), 3.82 (6H, s, 2×-OCH3), 3.733.70 (2H, m, -NHCH2CH2CH2N), 2.34 (2H, t, J = 5.4 Hz, -NHCH2CH2CH2N), 1.92 (6H, s, N(CH3)2), 1.71-1.67 (2H, p, J = 12 Hz, -NHCH2CH2CH2N).

C NMR (150 MHz, CDCl3) δ

13

163.1 (C2), 161.4 (C7), 161.1 (C3’, C5’), 160.1 (C8a), 159.5 (C4), 138.8 (C1’), 134.3 (C5),
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123.7 (C6), 108.8 (C4a), 107.2 (C2’, C6’), 100.0 (C4’), 59.2 (-NHCH2CH2CH2N), 55.4 (OCH3), 44.9 (-N(CH3)2), 42.5 (-NHCH2CH2CH2N), 24.9 (-NHCH2CH2CH2N). ES-MS [M+1]
found 382.2, calculated for C20H27N6O2 382.2.
N7-(3-(Dimethylamino)propyl)-6-(1H-indol-6-yl)pyrido[2,3-d]pyrimidine-2,7-diamine
(53). Column chromatography (94.5/5/0.5 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 53 (yield
71%) as a pale yellow solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.18). 1H NMR (600
MHz, CDCl3) δ 11.23 (1H, s, -InNH), 8.62 (1H, s, -ArH4), 7.65 (1H, d, J = 8.0 Hz, -InH4’),
7.55 (1H, s, -ArH5), 7.42 (1H, t, J = 2.8 Hz, -InH2’), 7.40 (1H, s, -InH7’), 7.27 (1H, t, J = 5.2
Hz, -InH3’), 6.99 (1H, dt, J = 8.1, 1.1 Hz, -InH5’), 6.60 (2H, s, -NH2), 6.49 (1H, t, J = 2.5 Hz,
-NH), 3.46 (2H, q, J = 6.1 Hz, -NHCH2CH2CH2N), 2.24 (2H, s, -NHCH2CH2CH2N), 1.82 (6H,
s, -N(CH3)2), 1.63 (2H, p, J = 6.4 Hz, -NHCH2CH2CH2N).

C NMR (150 MHz, CD3OD) δ
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162.8 (C2), 161.1 (C7), 160.7 (C8a), 159.3 (C4), 136.5 (C6’), 134.7 (C5), 128.8 (C7’a),
128.1 (C3’a), 125.4 (C2’), 125.3 (C6), 120.6 (C4’), 119.7 (C5’), 111.5 (C7’), 108.6 (C4a),
101.0 (C4’), 57.4 (-NHCH2CH2CH2N), 43.6 (-N(CH3)2), 40.2 (-NHCH2CH2CH2N), 25.4 (NHCH2CH2CH2N). ES-MS [M+1] found 362.3, calculated for C20H24N7 362.2.
N7-(3-(Dimethylamino)propyl)-6-(1H-indol-5-yl)pyrido[2,3-d]pyrimidine-2,7-diamine
(54). Column chromatography (97/3/0 to 94.5/5/0.5 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave
54 (yield 69%) as a yellow solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.41). 1H NMR
(600 MHz, CDCl3) δ 9.17 (1H, s, -InNH), 8.55 (1H, s, -ArH4), 7.63 (1H, s, -InH4’), 7.48 (1H,
d, J = 8.3 Hz, -InH6’), 7.43 (1H, s, -ArH5), 7.31 (1H, s, -InH7’), 7.24 (1H, t, J = 2.7 Hz, -NH),
7.13 (1H, d, J = 8.2 Hz, -InH2’), 6.57 (1H, t, J = 2.4 Hz, -InH3’), 5.34 (2H, s, -NH2), 3.7 (2H,
q, J = 5.7 Hz, -NHCH2CH2CH2N), 2.28 (2H, t, J = 6.1 Hz, -NHCH2CH2CH2N), 1.78 (6H, s, N(CH3)2), 1.67 (2H, p, J = 6.2 Hz, -NHCH2CH2CH2N).

C NMR (150 MHz, CDCl3) δ 162.8
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(C2), 161.3 (C8a), 161.0 (C7), 159.3 (C4), 135.6 (C5’), 134.5 (C5), 128.3 (C7’a), 127.8
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(C3’a), 125.4 (C2’), 125.3 (C6), 123.0 (C4’), 121.3 (C6’), 111.7 (C7’), 109.3 (C4a), 102.6
(C3’), 58.8 (-NHCH2CH2CH2N), 44.8 (-N(CH3)2), 42.0 (-NHCH2CH2CH2N), 25.3 (NHCH2CH2CH2N). ES-MS [M+1] found 362.2, calculated for C20H24N7 362.2.
6-(Cyclohex-1-en-1-yl)-N7-(3-(dimethylamino)propyl)pyrido[2,3-d]pyrimidine-2,7diamine (55). Column chromatography (99/1/0 to 97/3/0 to 94.5/5/0.5 to 89/10/1
CH2Cl2/MeOH/NH4OH) gave 55 (yield 71%) as a brown solid. TLC (89/10/1
CH2Cl2/MeOH/NH4OH, Rf = 0.35). 1H NMR (600 MHz, CDCl3) δ 8.51 (1H, s, -ArH4), 7.28
(1H, s, -ArH5), 6.89 (1H, t, J = 5.1 Hz, -NH), 5.83 (1H, dq, J = 3.8, 1.8 Hz, -cyhxH2’), 5.17
(2H, s, -NH2), 3.73 (2H, q, J = 5.7 Hz, -NHCH2CH2CH2N), 2.46 (2H, t, J = 6.1 Hz, NHCH2CH2CH2N), 2.27 (6H, s, -N(CH3)2), 2.24-2.16 (4H, m, cyhxH), 1.84-1.73 (4H, m,
cyhxH), 1.76-1.67 (2H, m, -NHCH2CH2CH2N).
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C NMR (150 MHz, CDCl3) δ 162.8 (C2),

160.9 (C8a), 160.0 (C7), 159.2 (C4), 134.1 (C1’), 132.7 (C5), 128.9 (C2’), 126.1 (C6), 109.0
(C4a), 59.1 (-NHCH2CH2CH2N), 45.6 (-N(CH3)2), 41.7 (-NHCH2CH2CH2N), 29.3 (C6’), 25.6
(-NHCH2CH2CH2N), 25.4 (C3’), 22.9 (C5’), 21.8 (C4’). ES-MS [M+1] found 327.2, calculated
for C18H27N6 327.2.

Scheme 19. Synthesis of 56. Reagents and conditions: (a) BBr3, CH2Cl2, 0 ºC, 2 h, 9%.
5-(2-Amino-7-((3-(dimethylamino)propyl)amino)pyrido[2,3-d]pyrimidin-6yl)benzene-1,3-diol (56). The synthesis of compound 56 followed the same procedure as
for compound 14. A cation exchange column was used for purification. The phosphate
cellulose resin (Whatman P11 cation exchange) was prepared by soaking the resin in water
for 30 min before packing. A solution of 1 mL sat. NH4Cl in 25 mL water was used to charge
the resin followed by flushing with water to remove the excess salt. The material was
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dissolved in water to load onto the column. The column was eluted by ammonia gradient
(0-0.8%) and monitored by TLC (78/20/2 CH2Cl2/MeOH/NH4OH, Rf = 0.42). The fractions
containing the desired product was pooled and lyophilized to give 56 as a white solid (yield
9%). 1H NMR (600 MHz, CD3OD) 9.42 (1H, s, -ArH4), 8.58 (1H, s, -ArH5), 6.58 (2H, d, J =
2.1 Hz, -PhH2’, 6’), 6.24 (1H, t, J = 2.1 Hz, -PhH4’), 3.49 (2H, q, J = 6.1 Hz, NHCH2CH2CH2N), 2.38 (2H, s, -NHCH2CH2CH2N), 1.98 (6H, s, -N(CH3)2), 1.63 (2H, p, J =
6.4 Hz, -NHCH2CH2CH2N).

C NMR (150 MHz, CD3OD) δ 162.4 (C2), 160.0 (C7), 159.4
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(C3’), 156.5 (C8a), 148.1 (C4), 139.9 (C1’), 137.2 (C5), 118.7 (C6), 110.8 (C4a), 107.2 (C2’),
103.5 (C4’), 47.2 (-N(CH3)2), 43.0 (-NHCH2CH2CH2N), 42.0 (-NHCH2CH2CH2N), 26.3 (NHCH2CH2CH2N). ES-MS [M+1] found 355.2, calculated for C18H23N6O2 355.2.

Scheme 20. Synthesis of 57. Reagents and conditions: (a) 10% Pd/C, H2, 40 psi, r.t., 2 h,
46%.
6-Cyclohexyl-N7-(3-(dimethylamino)propyl)pyrido[2,3-d]pyrimidine-2,7-diamine
(57)200. A solution of 55 (26 mg, 0.08 mmol) in MeOH (10 mL) was degassed and purged
with argon three times. To the solution, 10% Pd on activated carbon (6 mg) was added. The
argon was evacuated and exchanged with H2 gas three times and the reaction was shaken
under H2 at 40 psi for 2 h. The mixture was filtered through Celite and the filtrate was dried
in vacuo. Column chromatography (99/1/0 to 97/3/0 to 94.5/5/0.5 CH2Cl2/MeOH/NH4OH)
gave 57 (12 mg, yield 46%) as a brown solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf =
0.35). 1H NMR (600 MHz, CDCl3) δ 8.53 (1H, s, -ArH4), 7.84 (1H, s, -NH), 7.38 (1H, s, ArH5), 5.10 (2H, s, -NH2), 3.78 (2H, q, J = 5.4 Hz, -NHCH2CH2CH2N), 2.55 (2H, t, J = 5.4
Hz, -NHCH2CH2CH2N), 2.37-2.29 (7H, m, -N(CH3)2, cyhxH1’), 1.97-1.87 (4H, m, cyhxH),
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1.87-1.77 (3H, m, cyhxH), 1.44-1.25 (5H, m, -NHCH2CH2CH2N, cyhxH). 13C NMR (150 MHz,
CDCl3) δ 162.6 (C2), 160.4 (C6), 160.4 (C7a), 159.0 (C3), 130.2 (C4), 127.4 (C5), 109.2
(C3a), 60.1 (-NHCH2CH2CH2N), 45.6 (-N(CH3)2), 43.3 (-NHCH2CH2CH2N), 37.6 (C1’), 32.8
(C2’), 27.1 (C3’), 26.2 (-NHCH2CH2CH2N), 24.5 (C4’). ES-MS [M+1] found 329.2, calculated
for C18H29N6 329.2.
General method for the synthesis of 1,8-napthyridines (67-70). 2-Ethoxyethanol
was dried over K2CO3, distilled and stored over molecular sieves. To a solution of sodium
2-ethoxyethoxide (2 eq), prepared from NaH and 2-ethoxyethanol, was added various
acetonitriles (2 eq). The mixture was stirred under argon at room temperature for 30 min to
3 h. To the reaction, 9a (1 eq) was added and the reaction was heated at reflux for 3 to 7 h.
The reaction was cooled to room temperature, poured into cold water and chilled at 4 °C
overnight. The emulsion was transferred into a separation funnel and extracted by EtOAc 3
times. The organic layer was combined and washed with brine and then dried over MgSO4.
After concentration to dryness in vacuo the residue was purified by column chromatography
using the conditions listed below.
3-Phenyl-1,8-naphthyridine-2,7-diamine (67). Column chromatography (97/3/0 to
89/10/1 CH2Cl2/MeOH/NH4OH) gave 67 (yield 74%) as a yellow solid. TLC (94/5/1
CH2Cl2/MeOH/NH4OH, Rf = 0.22). 1H NMR (600 MHz, DMSO-d6) δ 7.68 (2H, d, J = 8.4 Hz,
-ArH4), 7.58 (1H, s, -ArH5), 7.48-7.47 (4H, m, -Ph2’, 3’), 7.40-7.37 (1H, m, -Ph4’), 6.45-6.43
(3H, m, -ArH3, -NH2), 5.97 (2H, s, -NH2). 13C NMR (150 MHz, DMSO-d6) δ 161.0 (C2), 157.8
(C7), 146.6 (C8a), 138.4 (C1’), 137.6 (C5), 137.6 (C4), 129.4 (C3’, C5’), 129.1 (C2’, C6’),
127.8 (C4’), 119.3 (C6), 114.9 (C4a), 107.8 (C3). ES-MS [M+1] found 237.1, calculated for
C14H13N4 237.1.
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3-(2,6-Dichlorophenyl)-1,8-naphthyridine-2,7-diamine

(68).

Column

chromatography (97/3/0 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 68 (yield 19%) as a yellow
solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.45). 1H NMR (600 MHz, DMSO-d6) δ 7.65
(1H, d, J = 9.0 Hz, -ArH4), 7.56 (2H, d, J = 8.4 Hz, -Ph3’, 5’), 7.47 (1H, s, -ArH5), 7.43 (1H,
t, J = 8.4 Hz), 6.51 (2H, s, -NH2), 6.42 (1H, d, J = 8.4 Hz, -ArH3), 5.92 (2H, s, -NH2).
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C

NMR (150 MHz, DMSO-d6) δ 161.0 (C2), 157.5 (C5), 157.0 (C8a), 138.2 (C4), 137.8 (C7),
135.8 (C2’, C6’), 135.3 (C1’), 131.0 (C4’), 129.0 (C3’, C5’), 114.7 (C6), 110.0 (C4a), 107.6
(C3). ES-MS [M+1] found 305.0, calculated for C14H13N4 305.0.
3-(3,5-Dimethylphenyl)-1,8-naphthyridine-2,7-diamine

(69).

Column

chromatography (97/3/0 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 69 (yield 79%) as a yellow
solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.5 2). 1H NMR (600 MHz, DMSO-d6) δ
7.64 (2H, d, J = 8.4 Hz, -ArH4), 7.51 (1H, s, -ArH5), 7.04 (2H, s, -Ph2’, 6’), 6.98 (1H, s, Ph4’), 6.40 (1H, d, J = 8.4 Hz, -ArH3), 6.35 (2H, s, -NH2), 5.87 (2H, s, -NH2), 2.30 (6H, s, CH3).

C NMR (150 MHz, DMSO-d6) δ 161.0 (C2), 157.8 (C7), 156.2 (C8a), 138.3 (C3’,
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C5’), 138.2 (C1’), 137.5 (C5), 137.2 (C4), 129.2 (C4’), 126.8 (C2’, C6’), 119.4 (C6), 110.9
(C4a), 107.7 (C3). ES-MS [M+1] found 265.1, calculated for C16H16N4 265.1.
3-(3,5-Dimethoxyphenyl)-1,8-naphthyridine-2,7-diamine

(70).

Column

chromatography (97/3/0 to 89/10/1 CH2Cl2/MeOH/NH4OH) gave 70 (yield 97%) as a yellow
solid. TLC (89/10/1 CH2Cl2/MeOH/NH4OH, Rf = 0.25). 1H NMR (600 MHz, DMSO-d6) δ 7.67
(2H, d, J = 8.4 Hz, -ArH4), 7.61 (1H, s, -ArH5), 6.60 (2H, d, J = 1.8 Hz, -Ph2’, 6’), 6.51 (1H,
t, J = 2.1 Hz, -Ph4’), 6.44-6.43 (3H, m, -ArH3, -NH2), 6.05 (2H, s, -NH2), 3.79 (6H, s, -OCH3).
C NMR (150 MHz, DMSO-d6) δ 162.1 (C3’, C5’), 161.0 (C2), 157.7 (C7), 156.6 (C8a),
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140.3 (C1’), 137.6 (C5), 137.4 (C4), 119.2 (C6), 110.7 (C4a), 107.8 (C3), 107.0 (C2’, C6’),
100.0 (C4’), 55.7 (OCH3). ES-MS [M+1] found 297.1, calculated for C14H13N4 297.1.
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5.2 Biology
B-PER (Pierce Biotechnologies) were purchased from Fisher. Ampicillin sodium salt,
Isopropyl β-D-1 thiogalactopyranoside (IPTG) and HisPur Cobalt resin were purchased
from Gold Biotechnology. ATP was purchased from Sigma-Aldrich. PEP, NADH were
purchased from Acros. AIR and CAIR were synthesized using literature methods73-74, 104.
PurK from A. clavatus was purified and stored according to the published methods139-140.
PurK from E. coli was purified by Jordan Rantucci and stored at -80 ºC. All proteins were
determined to be >95% pure based on SDS-PAGE analysis. Buffers were stored at 4 ºC
and stock solutions were stored at -20 ºC. Recombinant cells were purchased from Fisher
and stored at -80 ºC. During assays, reagents and enzyme were stored on crushed ice.
UV assays were carried in 1 mL quartz cuvettes on a 1-Bio Cary-3 UV-vis
spectrophotometer equipped with a temperature controller (Varian) or in flat-bottom 96 well
plates using a Synergy2 plate reader (BioTek). Thermal shift assays were conducted on a
Mx3005P qPCR System. Curve fitting was conducted using GraphPad Prism.
5.2.1 Phosphate Assay (Malachite green assay)
Reactions were conducted in a flat-bottom 96-well plate (USA Scientific 655101). Buffer
(190 µL) was added to each well of the plate (100 mM HEPES, pH 7.8 buffer containing 20
mM KCl and 6.0 mM MgCl2) followed by the addition of 100 µM AIR, 100 µM ATP, 1 mM
NaHCO3 and 0.01% (v/v) triton. Compound stocks in DMSO (10 µL, 5% v/v) were added
to the sample wells. For single concentration testing, the compound concentration was 200
µM unless restricted by solubility. Each compound was dispensed into six wells using a
single channel pipette. To three wells, PurK (𝐴𝑠𝑎𝑚 ) was added (see below for details) and
to the remaining three wells, the same volume of buffer was added with these wells serving
as UV background for that particular compound (𝐶𝑠𝑎𝑚 ). For dose-response testing, a series
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of concentrations selected around the estimated IC50 were used, and each concentration
was tested in triplicate. For kinetic assays, additional variables included ATP concentrations.
Each plate contained three wells of positive controls (5% DMSO + PurK) (𝐴𝐷𝑀𝑆𝑂 ) and three
wells of negative controls (5% DMSO) (𝐶𝐷𝑀𝑆𝑂 ). Compound 1 served as internal quality
controls for plates tested on different days. In the reaction wells, 168 ng PurK in 4 µL of
buffer was added. The UV background and negative control wells were supplemented with
4 µL of buffer. The reactions were incubated at room temperature for 15 minutes and were
quenched by the addition of 50 μL of the malachite green reagent (Bioassay Systems) to
each well. The plates were incubated at room temperature for an additional 30 minutes and
the absorbance (620 nm) of each well was measured using a Synergy2 plate reader by
BioTek. The quality of the plate was verified by the percent residual activity (RA%) of
compound 1 (43 ± 5%). The plates that passed the quality check were used to calculate the
RA% of other compounds based on Equation 2. For plates in which the RA% of compound
1 met the quality cut but was not 43%, RA% of all the compounds were further normalized
so that RA% of compound 1 was 43%.
𝑅𝐴% =

𝐴𝑠𝑎𝑚 − 𝐶𝑠𝑎𝑚
× 100%
𝐴𝐷𝑀𝑆𝑂 − 𝐶𝐷𝑀𝑆𝑂

Eq. 2

5.2.2 PK/LDH coupled PurK assay
Reactions were conducted in a 1 mL quartz cuvette at 37 ºC. A master mix containing
the following components (100 mM HEPES, pH 7.5, 20 mM KCl, 6 mM MgCl2, AIR 25 µM,
100 µM ATP, NADH 200 µM, PEP 2 mM, triton 0.01% (v/v), 1 mM NaHCO 3, 5 units of
pyruvate kinase/lactate dehydrogenase) was made to ensure consistency. The assay was
run as follows. Master mix (950 µL) was added to the cuvette followed by the addition of
compound stock in DMSO; the final DMSO concentration is 5% (v/v). For single
concentration testing, the compound concentration was 200 µM unless restricted by
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solubility or high UV absorbance. For dose-response testing, a series of concentrations
selected around the estimated IC50 were used, and each concentration was tested in triplet.
For kinetic assays, additional variables included ATP concentrations. The reaction was
initiated by the addition of 70 ng PurK. NADH oxidation was monitored at 340 nm and the
initial velocity of each assay was determined from the slope of the change in absorbance
during the first three minutes.
5.2.3 Thermal shift assay
Reactions were conducted in a 200 µM PCR tubes with clear lids. The total volume of
each reaction is 20 µL. MES buffer (20 mM, pH 6.0) was added followed by the addition of
0.01 % (v/v) triton, 5x SYPRO Orange and 2 µM PurKAsp (mw 45 kDa calculated as a
monomer). A series of concentrations of the compound to be tested (stocks in DMSO) were
added and the final DMSO concentration was kept at 5% (v/v). Thermal melting curve was
collected using a RT-PCR instrument (Mx3005P qPCR System) from 25-95 ºC (ramp rate:
1 ºC/minute) while monitoring the fluorescence of SYPRO Orange (ex = 492 nm, em = 610
nm). The melting temperature (Tm) was calculated from the maximum of the first derivate
curve. The dissociation constant Kd was calculated in GraphPad Prism based on a single
binding model following Equation 3.
𝒀 = 𝑻𝒎𝒎𝒊𝒏 + (𝑻𝒎𝒎𝒂𝒙 − 𝑻𝒎𝒎𝒊𝒏 ) × (𝟏

Eq. 2

(𝑷 + 𝑿 + 𝑲𝒅 )𝟐 − (𝟒 × 𝑷 × 𝑿)
− (𝑷 − 𝑲𝒅 − 𝑿 + √
))
𝟐×𝑷
𝑻𝒎𝒎𝒂𝒙 : Melting temperature at infinite inhibitor concentration. 𝑻𝒎𝒎𝒊𝒏 : Melting
temperature at no inhibitor concentration. 𝑃: Protein concentration (2 µM). 𝑋: Inhibitor
concentration in log unit.
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5.2.4 Construction, expression and purification of PurK mutant proteins.
The PurKAsp-pET28 plasmid with an N-terminal His tag of the following sequence
(MGSSHHHHHHSSENLYFQGH) was used to generate the desired mutant proteins. The
plasmids for the mutant proteins were generated following the protocol of the Quikchange
II site-directed mutagenesis kit (Agilent Technologies) using the primers listed in Table 11.
The nucleotide sequence of each mutant protein was verified by Sanger sequencing at the
Applied Genomics Technology Center, Wayne State University. The plasmids obtained
from the mutagenesis was transformed into E. coli BL21(DE3) pLysS recombinant cells for
protein expression and purification. The expression and purification of the proteins were
following established methods for PurKAsp139, 142. The purified N-His proteins were used
directly without cleavage of the His tag.
Table 11. Primers used for the creation of mutant PurKAsp.
Mutant

Primers

C266A

5’ cagcatca tgctggccga gatcgccagc 3’
5’ gctggcgatc tcggccagca tgatgctg 3’

C266S

5’ cagcatca tgctgagcga gatcgccagc 3’
5’ gctggcgatc tcctcagca tgatgctg 3’

C216S

5’ ggaggact cgatatccaa gctcgtgtacgcg 3’
5’ cgcgtacacgagc ttggatatcg agtcctcc 3’

5.2.5 PK/LDH coupled PurK assay used in the study of cysteines functions
The reactions were run similar as described in section 5.2.2 with N-methyl maleimide
used as the inhibitor. For continuous assay, the reactions were initiated with the protein
addition. For reactions where PurK was pre-incubated with N-methyl maleimide, the
PurK/N-methyl maleimide mixture was used to initiate the reaction.
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The spread of drug-resistant bacterial infections has increased the need for novel
antimicrobial agents. One potential but unexplored target is the de novo purine biosynthetic
pathway. PurK, found only in bacteria, yeast, and fungi, catalyzes the sixth step in purine
biosynthesis and has no human homolog. Herein we disclose the discovery of the first PurK
inhibitor with submicromolar potency.
PurK is a member of the ATP-grasp superfamily of enzymes and recently, nanomolar
inhibitors of biotin carboxylase, a related enzyme, were published. We hypothesized that
those inhibitors, which target the ATP-binding site, could also inhibit PurK. To explore this
hypothesis, four compounds were synthesized and tested against PurK from A. clavatus.
Only one compound, 1 containing a pyridopyrimidine core, weakly inhibits PurKAsp with an
IC50 of 167 μM. Kinetic assays have confirmed that 1 is an ATP-competitive inhibitor. With
the guidance of computational modeling, further optimizations have been focused on the
ribose and phosphate positions within the ATP-binding site. Both positions gave
compounds with improved activities. A double-modified compound, 56, merging the best
compound from each position, inhibits PurKAsp with an IC50 of 1.7 µM, a 100-fold
improvement in potency. The binding affinity was validated by thermal shift assays. 56 is
the most potent ATP-binding site inhibitor against PurKAsp described to date.
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